metronidazole has been researched along with Rosacea in 233 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
Rosacea: A cutaneous disorder primarily of convexities of the central part of the FACE, such as FOREHEAD; CHEEK; NOSE; and CHIN. It is characterized by FLUSHING; ERYTHEMA; EDEMA; RHINOPHYMA; papules; and ocular symptoms. It may occur at any age but typically after age 30. There are various subtypes of rosacea: erythematotelangiectatic, papulopustular, phymatous, and ocular (National Rosacea Society's Expert Committee on the Classification and Staging of Rosacea, J Am Acad Dermatol 2002; 46:584-7).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Topical metronidazole is not currently approved in Japan as a treatment for the indication of rosacea, although 0." | 9.51 | Metronidazole gel (0.75%) in Japanese patients with rosacea: A randomized, vehicle-controlled, phase 3 study. ( Fujii, C; Fujita, T; Miyachi, Y; Yamasaki, K, 2022) |
| "The results of this relapse study showed that an initial successful treatment with ivermectin 1% cream QD significantly extended remission of rosacea compared with initial treatment with metronidazole 0." | 9.22 | Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study. ( Barańska-Rybak, W; Berth-Jones, J; Briantais, P; Jacovella, J; Khemis, A; Passeron, T; Ruzicka, T; Schauber, J; Taieb, A, 2016) |
| "Dapsone gel was as effective as metronidazole gel in the treatment of papulopustular rosacea." | 9.20 | Dapsone Gel in the Treatment of Papulopustular Rosacea: A Double-Blind Randomized Clinical Trial. ( Assaf, F; Faghihi, G; Hosseini, SM; Khosravani, P; Nilforoushzadeh, MA; Smiley, A; Zeinali, N, 2015) |
| "The aim of this study was to prepare a topical water-in-oil type microemulsion containing metronidazole and to compare its effectiveness with a commercial gel product in the treatment of rosacea." | 9.16 | Preparation and evaluation of topical microemulsion system containing metronidazole for remission in rosacea. ( Adişen, E; Çelebi, N; Erel, A; Kayiş, A; Tirnaksiz, F, 2012) |
| "In this single-blind, 8-week study, we investigated the potential efficacy and safety of terbinafine 1% cream for the treatment of mild and moderate papulopustular rosacea, and compared the results with those of 0." | 9.15 | Efficacy of 1% terbinafine cream in comparison with 0.75% metronidazole gel for the treatment of papulopustular rosacea. ( Serdar, ZA; Yaşar, Ş, 2011) |
| "To compare the efficacy and safety of pimecrolimus 1% cream and metronidazole 1% cream in the treatment of patients with papulopustular rosacea (PR)." | 9.14 | A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. ( Altinyazar, HC; Ankarali, H; Cinar, S; Koca, R; Muhtar, S; Tekin, NS, 2010) |
| "A phase 4, open-label, multicenter, community-based study was conducted in subjects with mild to moderately severe papulopustular rosacea of various etiologies and locations to identify subgroups particularly responsive to twice-daily application of metronidazole topical gel 0." | 9.12 | The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. ( Del Rosso, JQ; Wolf, JE, 2007) |
| " We aimed to show that benzoyl peroxide-erythromycin gel is efficient in the treatment of acne rosacea." | 9.11 | Efficiency of benzoyl peroxide-erythromycin gel in comparison with metronidazole gel in the treatment of acne rosacea. ( Afşar, FS; Ermertcan, AT; Oztürkcan, S; Sahin, MT, 2004) |
| "Adapalene gel is well tolerated and can be used as an alternative for topical treatment of papulopustular rosacea." | 9.11 | Adapalene vs. metronidazole gel for the treatment of rosacea. ( Altinyazar, HC; Eştürk, E; Koca, R; Tekin, NS, 2005) |
| "Topical metronidazole and combination sodium sulfacetamide and sulfur commonly are used to treat rosacea." | 9.11 | Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. ( Dunlap, FE; Egan, N; Jarratt, M; Stewart, D; Torok, HM; Webster, G, 2005) |
| "Subantimicrobial doses of doxycycline may improve outcomes in rosacea when combined with topical metronidazole and used as maintenance monotherapy." | 9.11 | A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. ( Almodóvar, PI; Bradshaw, M; Powala, C; Sanchez, J; Somolinos, AL; Webster, G, 2005) |
| "It can be concluded that the application of permethrin 5% cream twice daily for 2 months can be as effective and reliable as metronidazole in the treatment of rosacea and a greater benefit can be gained when it is combined with other systemic and/or topical treatments." | 9.10 | Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study. ( Ekşioğlu, M; Koçak, M; Vahapoğlu, G; Yağli, S, 2002) |
| "75% metronidazole gel in improving principal signs of rosacea (inflammatory lesions and erythema)." | 9.10 | A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. ( Elewski, BE; Fleischer, AB; Pariser, DM, 2003) |
| "The papules and pustules of rosacea can be effectively treated with topical metronidazole." | 9.09 | Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. ( Baker, MD; Dahl, MV; Jarratt, M; Kaplan, D; Tuley, MR, 2001) |
| "Metronidazole topical gel may be a safe and effective means of treating rosacea blepharitis." | 9.08 | The efficacy of topical metronidazole in the treatment of ocular rosacea. ( Barnhorst, DA; Chern, KC; Foster, JA; Meisler, DM, 1996) |
| "To determine if the use of topical metronidazole gel (Metrogel) could prevent relapse of moderate to severe rosacea." | 9.08 | Topical metronidazole maintains remissions of rosacea. ( Aly, R; Baker, MO; Bayles, C; Coleman, E; Czernielewski, JM; Dahl, MV; Herndon, JH; Katz, HI; Krueger, GG; Millikan, LE; Odom, RB; Parker, F; Patrignelli, R; Reusser, B; Tuley, MR; Weidner, M; Wolf, JE, 1998) |
| "The proven value of tetracyclines and metronidazole administered orally in the treatment of the chronic and recurrent disease that is rosacea is tempered by the important undesirable effects observed in long-term therapy." | 9.07 | [Double-blind study versus excipient of 0.75% metronidazole gel in the treatment of rosacea]. ( Archimbaud, A; Baspeyras, M; Boitier, F; Bussière, M; Chamberlin, J; Coin, A; Di Crescenzo, MC; Dolivo, M; Espagne, E; Guillaume, JC, 1993) |
| "One percent metronidazole in an emollient cream base was compared with 250 mg oral tetracycline taken twice daily for the treatment of seventy-five patients with rosacea." | 9.06 | Topical metronidazole in the treatment of rosacea. ( Christiansen, JV; Hjorth, N; Schmidt, H; Veien, NK, 1986) |
| "Eighty-one patients with rosacea were treated with either I% metronidazole cream or the cream base as a placebo for two months." | 9.05 | Treatment of rosacea with i% metronidazole cream. A double-blind study. ( Nielsen, PG, 1983) |
| "In a randomized double-blind trial fifty-one patients with rosacea were treated for 2 months with either I% metronidazole cream and placebo tablets or with 250 mg oxytetracycline tablets taken twice daily, and placebo cream (the cream base)." | 9.05 | A double-blind study of I% metronidazole cream versus systemic oxytetracycline therapy for rosacea. ( Nielsen, PG, 1983) |
| "Forty patients with papulo-pustular rosacea were treated for 12 weeks on a random double-blind basis either with oxytetracycline 250 mg twice daily or with metronidazole 200 mg twice daily." | 9.05 | A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. ( Burton, JL; Saihan, EM, 1980) |
| "A double-blind trial in twenty-nine patients with rosacea showed that, after 6 weeks' treatment, metronidazole was therapeutically superior to a placebo (P less than 0-02)." | 9.04 | Treatment of rosacea by metronidazole. ( Burton, JL; Pye, RJ, 1976) |
| "To review published studies about topical metronidazole therapy for rosacea, both as a monotherapy and in conjunction with oral antibiotics." | 8.84 | Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics. ( Balkrishnan, R; Conde, JF; Feldman, SR; Fleischer, AB; Yelverton, CB, 2007) |
| "Topical metronidazole is commonly used in the management of rosacea." | 8.83 | Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter? ( Kimball, AB; Reid, DC; Yoo, J, 2006) |
| "The chemistry, mechanism of action, pharmacokinetics, and adverse effects of topically applied metronidazole are reviewed, and the drug's use and efficacy in the treatment of rosacea and other conditions are discussed." | 8.78 | Topical metronidazole: a new therapy for rosacea. ( McEvoy, GK; Schmadel, LK, 1990) |
| "Metronidazole (MNZ) is a nitroimidazole derivative antibiotic that has been generally used in the treatment of rosacea." | 8.12 | Enhanced skin localization of metronidazole using solid lipid microparticles incorporated into polymeric hydrogels for potential improved of rosacea treatment: An ex vivo proof of concept investigation. ( Azhar, M; Himawan, A; Pakki, E; Permana, AD; Rahman, L; Saka Dwipayanti, K, 2022) |
| "The objective of the present investigation was to improve the skin deposition and retention of metronidazole (MTZ) in rosacea therapy by incorporating it into nanostructured lipid carriers (NLCs)." | 7.91 | Metronidazole-loaded nanostructured lipid carriers to improve skin deposition and retention in the treatment of rosacea. ( Easwaran, S; Parmar, SJ; Shinde, UA, 2019) |
| "Thirty-seven adult Caucasian patients (9 males and 28 females), with erythemato-telangiectatic rosacea accompanied by stinging and burning sensation, were treated with a cream containing 5% potassium azeloyl diglycinate and 1% hydroxypropyl chitosan." | 7.81 | Treatment of symptoms of erythemato-telangiectatic rosacea with topical potassium azeloyl diglycinate and hydroxypropyl chitosan: Results of a sponsor-free, multicenter, open study. ( Barbareschi, M; De Micheli, P; Raia, DD; Schianchi, R; Veraldi, S, 2015) |
| "Azelaic acid (AzA) 15% gel has been available in the United States for slightly over a decade, approved for treatment of the inflammatory lesions (papules and pustules) of rosacea." | 7.80 | Update on the management of rosacea: a status report on the current role and new horizons with topical azelaic acid. ( Del Rosso, JQ; Kircik, LH, 2014) |
| "To assess the effectiveness and tolerance of systemic metronidazole in the treatment of childhood ocular and cutaneous rosacea." | 7.77 | [Metronidazole: alternative treatment for ocular and cutaneous rosacea in the pediatric population]. ( Aitali, F; Boralevi, F; Chamaillard, M; Colin, J; Léauté-Labrèze, C; Léoni, S; Marques da Costa, C; Mesplié, N; Mortemousque, B; Taïeb, A, 2011) |
| "The objective of this study was to examine predictors of number of refills related to topical metronidazole and total healthcare costs in rosacea patients." | 7.74 | Prescription refills and healthcare costs associated with topical metronidazole in Medicaid enrolled patients with rosacea. ( Balkrishnan, R; Camacho, FT; Feldman, SR; Jayawant, SS; Yentzer, B, 2008) |
| "Permethrin 5% cream is a safe alternative for the topical treatment of papulopustular rosacea." | 7.72 | Is permethrin 5% cream effective for rosacea? ( Swenor, ME, 2003) |
| "Metronidazole is clinically effective in treating not only rosacea but also acne inflammation." | 7.68 | The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne. ( Akamatsu, H; Asada, Y; Nishijima, S; Niwa, Y; Oguchi, M; Takahashi, M; Ushijima, T, 1990) |
| "Twenty-two patients suffering from rosacea papulosa or rosacea papulo-pustulosa were treated with Metronidazole at a low dosage (125 or 250 mg/d) for 2 to 6 months." | 7.67 | [Treatment of rosacea with metronidazole internally and externally]. ( Prinz, L, 1984) |
| "To elucidate the mechanism of action of metronidazole in the treatment of rosacea, the effect of metronidazole on the generation of reactive oxygen species was examined both in neutrophil and xanthine-xanthine oxidase systems." | 7.67 | Anti-oxidant action of metronidazole: a possible mechanism of action in rosacea. ( Imamura, S; Miyachi, Y; Niwa, Y, 1986) |
| "Introduced on the basis of a primary incidental observation metronidazole has gained more and more interest in the treatment of rosacea." | 7.66 | [Metronidazole therapy of rosacea. The drug and its indications]. ( Braun-Falco, O; Korting, HC, 1983) |
| "Metronidazole was administered (500 mg daily the first month, 250 mg daily the second month and, in some cases, 250 mg every other day the following months) to 62 patients suffering from rosacea or perioral dermatitis." | 7.66 | [Metronidazole therapy in rosacea (author's transl)]. ( Guilhou, E; Guilhou, JJ; Malbos, S; Meynadier, J, 1979) |
| "Rosacea is a leading reason why people seek the care of a dermatologist, accounting for nearly 7 million office visits annually." | 6.75 | Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. ( Bruce, S; Del Rosso, JQ; Jarratt, M; Menter, A; Staedtler, G, 2010) |
| "Effective treatments for rosacea, including topical metronidazole and systemic antibiotics, have anti-inflammatory activity, which may be more important than their antimicrobial activity in this setting." | 6.73 | Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. ( Fowler, JF, 2007) |
| "Rosacea is an inflammatory dermatologic disorder characterized by the presence of facial erythema, visible blood vessels, papules, and pustules." | 6.72 | Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. ( Arsonnaud, S; Kerrouche, N; Wolf, JE, 2006) |
| "Acne rosacea is a common skin condition characterized by flushing episodes, erythema, telangiectasia, and recurrent crops of inflammatory papules and pustules that involve the face in a symmetrical distribution." | 6.68 | A pilot study of 5 percent permethrin cream versus 0.75 percent metronidazole gel in acne rosacea. ( Signore, RJ, 1995) |
| "Metronidazole was the first topical therapy approved for rosacea and is still considered the foundation therapy by many researchers and dermatologists." | 6.42 | The role of topical metronidazole in the treatment of rosacea. ( Wolf, JE, 2004) |
| "Rosacea is relatively common, typically occurring in individuals of Northern European and Celtic origin between 30 and 50 years of age." | 6.41 | Topical metronidazole for rosacea. ( Chaudhry, M; Gupta, AK, 2002) |
| "Nowadays, a wide range of treatments for rosacea is available: topical metronidazole, oral metronidazole, topical ivermectin, oral tetracyclines, oral isotretinoin, systemic steroids, photodynamic therapy, or pulsed dye laser." | 5.56 | Use of permethrin in the treatment of rosacea fulminans during pregnancy: One case report. ( Aguado García, Á; Garabito Solovera, E; Garayar Cantero, M; Manchado López, P; Ruiz Sánchez, D; Valtueña, J, 2020) |
| "Topical metronidazole is not currently approved in Japan as a treatment for the indication of rosacea, although 0." | 5.51 | Metronidazole gel (0.75%) in Japanese patients with rosacea: A randomized, vehicle-controlled, phase 3 study. ( Fujii, C; Fujita, T; Miyachi, Y; Yamasaki, K, 2022) |
| "Treatment with clarithromycin, metronidazole and pantoprazole eradicated H." | 5.31 | Resolution of granulomatous rosacea after eradication of Helicobacter pylori with clarithromycin, metronidazole and pantoprazole. ( Kaddu, S; Kränke, B; Mayr-Kanhäuser, S; Müllegger, RR, 2001) |
| "The results of this relapse study showed that an initial successful treatment with ivermectin 1% cream QD significantly extended remission of rosacea compared with initial treatment with metronidazole 0." | 5.22 | Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study. ( Barańska-Rybak, W; Berth-Jones, J; Briantais, P; Jacovella, J; Khemis, A; Passeron, T; Ruzicka, T; Schauber, J; Taieb, A, 2016) |
| "Dapsone gel was as effective as metronidazole gel in the treatment of papulopustular rosacea." | 5.20 | Dapsone Gel in the Treatment of Papulopustular Rosacea: A Double-Blind Randomized Clinical Trial. ( Assaf, F; Faghihi, G; Hosseini, SM; Khosravani, P; Nilforoushzadeh, MA; Smiley, A; Zeinali, N, 2015) |
| "Several studies were performed to evaluate the efficacy of this product in the management of rosacea prone skin, as either monotherapy or adjunctive therapy or to maintain the efficacy of a Metronidazole treatment." | 5.17 | Management of rosacea-prone skin: evaluation of a skincare product containing Ambophenol, Neurosensine, and La Roche-Posay Thermal spring water as monotherapy or adjunctive therapy. ( Bayer, M; Benech, F; Berdah, S; Gibejova, L; Sakalikova, M; Segot, E; Seite, S; Veyrat, S; Zelenkova, H, 2013) |
| "The aim of this study was to prepare a topical water-in-oil type microemulsion containing metronidazole and to compare its effectiveness with a commercial gel product in the treatment of rosacea." | 5.16 | Preparation and evaluation of topical microemulsion system containing metronidazole for remission in rosacea. ( Adişen, E; Çelebi, N; Erel, A; Kayiş, A; Tirnaksiz, F, 2012) |
| "In this single-blind, 8-week study, we investigated the potential efficacy and safety of terbinafine 1% cream for the treatment of mild and moderate papulopustular rosacea, and compared the results with those of 0." | 5.15 | Efficacy of 1% terbinafine cream in comparison with 0.75% metronidazole gel for the treatment of papulopustular rosacea. ( Serdar, ZA; Yaşar, Ş, 2011) |
| "Thirty women with mild or moderate erythema of rosacea on their facial cheeks were randomly assigned to use one of the following for 28 days: the rosacea treatment system (RTS); RTS minus metronidazole (RTS-M); or metronidazole 0." | 5.15 | Efficacy of a novel rosacea treatment system: an investigator-blind, randomized, parallel-group study. ( Leyden, JJ, 2011) |
| "To compare the efficacy and safety of pimecrolimus 1% cream and metronidazole 1% cream in the treatment of patients with papulopustular rosacea (PR)." | 5.14 | A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. ( Altinyazar, HC; Ankarali, H; Cinar, S; Koca, R; Muhtar, S; Tekin, NS, 2010) |
| "Topical ivermectin was more effective than metronidazole, but has a more concerning pregnancy category." | 5.12 | Treatment of rosacea during pregnancy. ( Cline, A; Gomolin, T; Pereira, F, 2021) |
| "A phase 4, open-label, multicenter, community-based study was conducted in subjects with mild to moderately severe papulopustular rosacea of various etiologies and locations to identify subgroups particularly responsive to twice-daily application of metronidazole topical gel 0." | 5.12 | The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. ( Del Rosso, JQ; Wolf, JE, 2007) |
| "Adapalene gel is well tolerated and can be used as an alternative for topical treatment of papulopustular rosacea." | 5.11 | Adapalene vs. metronidazole gel for the treatment of rosacea. ( Altinyazar, HC; Eştürk, E; Koca, R; Tekin, NS, 2005) |
| "Topical metronidazole and combination sodium sulfacetamide and sulfur commonly are used to treat rosacea." | 5.11 | Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. ( Dunlap, FE; Egan, N; Jarratt, M; Stewart, D; Torok, HM; Webster, G, 2005) |
| "Subantimicrobial doses of doxycycline may improve outcomes in rosacea when combined with topical metronidazole and used as maintenance monotherapy." | 5.11 | A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. ( Almodóvar, PI; Bradshaw, M; Powala, C; Sanchez, J; Somolinos, AL; Webster, G, 2005) |
| "It can be concluded that the application of permethrin 5% cream twice daily for 2 months can be as effective and reliable as metronidazole in the treatment of rosacea and a greater benefit can be gained when it is combined with other systemic and/or topical treatments." | 5.10 | Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study. ( Ekşioğlu, M; Koçak, M; Vahapoğlu, G; Yağli, S, 2002) |
| "75% metronidazole gel in improving principal signs of rosacea (inflammatory lesions and erythema)." | 5.10 | A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. ( Elewski, BE; Fleischer, AB; Pariser, DM, 2003) |
| "The papules and pustules of rosacea can be effectively treated with topical metronidazole." | 5.09 | Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. ( Baker, MD; Dahl, MV; Jarratt, M; Kaplan, D; Tuley, MR, 2001) |
| "Metronidazole topical gel may be a safe and effective means of treating rosacea blepharitis." | 5.08 | The efficacy of topical metronidazole in the treatment of ocular rosacea. ( Barnhorst, DA; Chern, KC; Foster, JA; Meisler, DM, 1996) |
| "To determine if the use of topical metronidazole gel (Metrogel) could prevent relapse of moderate to severe rosacea." | 5.08 | Topical metronidazole maintains remissions of rosacea. ( Aly, R; Baker, MO; Bayles, C; Coleman, E; Czernielewski, JM; Dahl, MV; Herndon, JH; Katz, HI; Krueger, GG; Millikan, LE; Odom, RB; Parker, F; Patrignelli, R; Reusser, B; Tuley, MR; Weidner, M; Wolf, JE, 1998) |
| "The proven value of tetracyclines and metronidazole administered orally in the treatment of the chronic and recurrent disease that is rosacea is tempered by the important undesirable effects observed in long-term therapy." | 5.07 | [Double-blind study versus excipient of 0.75% metronidazole gel in the treatment of rosacea]. ( Archimbaud, A; Baspeyras, M; Boitier, F; Bussière, M; Chamberlin, J; Coin, A; Di Crescenzo, MC; Dolivo, M; Espagne, E; Guillaume, JC, 1993) |
| "One percent metronidazole in an emollient cream base was compared with 250 mg oral tetracycline taken twice daily for the treatment of seventy-five patients with rosacea." | 5.06 | Topical metronidazole in the treatment of rosacea. ( Christiansen, JV; Hjorth, N; Schmidt, H; Veien, NK, 1986) |
| "Eighty-one patients with rosacea were treated with either I% metronidazole cream or the cream base as a placebo for two months." | 5.05 | Treatment of rosacea with i% metronidazole cream. A double-blind study. ( Nielsen, PG, 1983) |
| "In a randomized double-blind trial fifty-one patients with rosacea were treated for 2 months with either I% metronidazole cream and placebo tablets or with 250 mg oxytetracycline tablets taken twice daily, and placebo cream (the cream base)." | 5.05 | A double-blind study of I% metronidazole cream versus systemic oxytetracycline therapy for rosacea. ( Nielsen, PG, 1983) |
| "Forty patients with papulo-pustular rosacea were treated for 12 weeks on a random double-blind basis either with oxytetracycline 250 mg twice daily or with metronidazole 200 mg twice daily." | 5.05 | A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. ( Burton, JL; Saihan, EM, 1980) |
| "A double-blind trial in twenty-nine patients with rosacea showed that, after 6 weeks' treatment, metronidazole was therapeutically superior to a placebo (P less than 0-02)." | 5.04 | Treatment of rosacea by metronidazole. ( Burton, JL; Pye, RJ, 1976) |
| "There was high quality evidence to support the effectiveness of topical azelaic acid, topical ivermectin, brimonidine, doxycycline and isotretinoin for rosacea." | 4.91 | Interventions for rosacea. ( Carter, B; Charland, L; Fedorowicz, Z; van der Linden, MM; van Zuuren, EJ, 2015) |
| "Although the majority of included studies were assessed as being at high or unclear risk of bias there was some evidence to support the effectiveness of topical metronidazole, azelaic acid, and doxycycline (40 mg) in the treatment of moderate to severe rosacea, and cyclosporine 0." | 4.87 | Interventions for rosacea. ( Carter, B; Fedorowicz, Z; Graber, MA; Kramer, S; van Zuuren, EJ, 2011) |
| "To review published studies about topical metronidazole therapy for rosacea, both as a monotherapy and in conjunction with oral antibiotics." | 4.84 | Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics. ( Balkrishnan, R; Conde, JF; Feldman, SR; Fleischer, AB; Yelverton, CB, 2007) |
| "Azelaic acid (AzA) initially was released in a 20% cream formulation, which has been shown to be effective in the treatment of mild to moderate rosacea." | 4.83 | A clinical overview of azelaic acid. ( Elewski, B; Thiboutot, D, 2006) |
| "Topical metronidazole is commonly used in the management of rosacea." | 4.83 | Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter? ( Kimball, AB; Reid, DC; Yoo, J, 2006) |
| "The chemistry, mechanism of action, pharmacokinetics, and adverse effects of topically applied metronidazole are reviewed, and the drug's use and efficacy in the treatment of rosacea and other conditions are discussed." | 4.78 | Topical metronidazole: a new therapy for rosacea. ( McEvoy, GK; Schmadel, LK, 1990) |
| "The use of mesoderm therapy combined with compound glycyrrhizic acid has a therapeutic effect on facial rosacea and improves patient satisfaction." | 4.31 | Therapeutic effects of mesoderm introduction of compound glycyrrhizin injection on the treatment of rosacea. ( Chen, Y; Li, S; Liu, J; Zhao, X, 2023) |
| "Metronidazole (MNZ) is a nitroimidazole derivative antibiotic that has been generally used in the treatment of rosacea." | 4.12 | Enhanced skin localization of metronidazole using solid lipid microparticles incorporated into polymeric hydrogels for potential improved of rosacea treatment: An ex vivo proof of concept investigation. ( Azhar, M; Himawan, A; Pakki, E; Permana, AD; Rahman, L; Saka Dwipayanti, K, 2022) |
| "The objective of the present investigation was to improve the skin deposition and retention of metronidazole (MTZ) in rosacea therapy by incorporating it into nanostructured lipid carriers (NLCs)." | 3.91 | Metronidazole-loaded nanostructured lipid carriers to improve skin deposition and retention in the treatment of rosacea. ( Easwaran, S; Parmar, SJ; Shinde, UA, 2019) |
| "A pooled analysis was performed on 1366 rosacea subjects from four randomized controlled trials with IGA before and after treatment (ivermectin, metronidazole or vehicle)." | 3.85 | Defining treatment success in rosacea as 'clear' may provide multiple patient benefits: results of a pooled analysis. ( Jackson, JM; Kerrouche, N; Schäfer, G; Schaller, M; Tan, J; Webster, G, 2017) |
| "Twenty cancer patients being treated with EGFRIs were included in the study." | 3.85 | Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: a case series and a literature review of therapeutic approaches. ( Antoniou, C; Katsambas, A; Kiagia, M; Nikolaou, C; Nikolaou, V; Stratigos, A; Syrigos, K, 2010) |
| "Thirty-seven adult Caucasian patients (9 males and 28 females), with erythemato-telangiectatic rosacea accompanied by stinging and burning sensation, were treated with a cream containing 5% potassium azeloyl diglycinate and 1% hydroxypropyl chitosan." | 3.81 | Treatment of symptoms of erythemato-telangiectatic rosacea with topical potassium azeloyl diglycinate and hydroxypropyl chitosan: Results of a sponsor-free, multicenter, open study. ( Barbareschi, M; De Micheli, P; Raia, DD; Schianchi, R; Veraldi, S, 2015) |
| "Azelaic acid (AzA) 15% gel has been available in the United States for slightly over a decade, approved for treatment of the inflammatory lesions (papules and pustules) of rosacea." | 3.80 | Update on the management of rosacea: a status report on the current role and new horizons with topical azelaic acid. ( Del Rosso, JQ; Kircik, LH, 2014) |
| "Metronidazole and azelaic acid are the only topical medications approved for rosacea." | 3.79 | [Topical therapy of rosacea]. ( Schöfer, H, 2013) |
| "To assess the effectiveness and tolerance of systemic metronidazole in the treatment of childhood ocular and cutaneous rosacea." | 3.77 | [Metronidazole: alternative treatment for ocular and cutaneous rosacea in the pediatric population]. ( Aitali, F; Boralevi, F; Chamaillard, M; Colin, J; Léauté-Labrèze, C; Léoni, S; Marques da Costa, C; Mesplié, N; Mortemousque, B; Taïeb, A, 2011) |
| "A range of treatment options are available in rosacea, which include several topical (mainly metronidazole, azelaic acid, other antibiotics, sulfur, retinoids) and oral drugs (mainly tetracyclines, metronidazole, macrolides)." | 3.77 | [Treatment of rosacea]. ( Cozzani, E; Drago, F; Gallo, R; Paolino, S; Parodi, A, 2011) |
| "A range of treatment options are available in rosacea, which include several topical (mainly metronidazole, azelaic acid, other antibiotics, sulfur, retinoids) and oral drugs (mainly tetracyclines, metronidazole, macrolides)." | 3.77 | Treatment of rosacea. ( Cozzani, E; Drago, F; Gallo, R; Paolino, S; Parodi, A, 2011) |
| "The objective of this study was to examine predictors of number of refills related to topical metronidazole and total healthcare costs in rosacea patients." | 3.74 | Prescription refills and healthcare costs associated with topical metronidazole in Medicaid enrolled patients with rosacea. ( Balkrishnan, R; Camacho, FT; Feldman, SR; Jayawant, SS; Yentzer, B, 2008) |
| "Topical treatment of acne rosacea, a chronic condition characterized by recurrent course for many years, is primarily based on metronidazole preparations." | 3.74 | The effect of methylcellulose on metronidazole release from polyacrylic acid hydrogels. ( Musial, W, 2007) |
| "Permethrin 5% cream is a safe alternative for the topical treatment of papulopustular rosacea." | 3.72 | Is permethrin 5% cream effective for rosacea? ( Swenor, ME, 2003) |
| "A 68-year-old woman developed allergic contact dermatitis to topical metronidazole gel as proven by positive patch tests to the gel and to metronidazole." | 3.72 | Co-existing sensitivity to metronidazole and isothiazolinone. ( Matz, H; Orion, E; Wolf, R, 2003) |
| "Metronidazole is clinically effective in treating not only rosacea but also acne inflammation." | 3.68 | The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne. ( Akamatsu, H; Asada, Y; Nishijima, S; Niwa, Y; Oguchi, M; Takahashi, M; Ushijima, T, 1990) |
| "Twenty-two patients suffering from rosacea papulosa or rosacea papulo-pustulosa were treated with Metronidazole at a low dosage (125 or 250 mg/d) for 2 to 6 months." | 3.67 | [Treatment of rosacea with metronidazole internally and externally]. ( Prinz, L, 1984) |
| "To elucidate the mechanism of action of metronidazole in the treatment of rosacea, the effect of metronidazole on the generation of reactive oxygen species was examined both in neutrophil and xanthine-xanthine oxidase systems." | 3.67 | Anti-oxidant action of metronidazole: a possible mechanism of action in rosacea. ( Imamura, S; Miyachi, Y; Niwa, Y, 1986) |
| "Reports about a good effectiveness of systemic therapy of papular rosacea with metronidazole stimulated us to investigate the value of a local treatment 1) with metronidazole mixed in Ungt." | 3.66 | [Local treatment of rosacea with imidazole derivatives]. ( Döring, HF; Ilgner, M, 1983) |
| "Introduced on the basis of a primary incidental observation metronidazole has gained more and more interest in the treatment of rosacea." | 3.66 | [Metronidazole therapy of rosacea. The drug and its indications]. ( Braun-Falco, O; Korting, HC, 1983) |
| "Metronidazole was administered (500 mg daily the first month, 250 mg daily the second month and, in some cases, 250 mg every other day the following months) to 62 patients suffering from rosacea or perioral dermatitis." | 3.66 | [Metronidazole therapy in rosacea (author's transl)]. ( Guilhou, E; Guilhou, JJ; Malbos, S; Meynadier, J, 1979) |
| "Rosacea is likely to be underdiagnosed and undertreated in Japan because of the current lack of consensus guidelines and standardized therapy." | 3.11 | Perspectives on rosacea patient characteristics and quality of life using baseline data from a phase 3 clinical study conducted in Japan. ( Miyachi, Y; Yamasaki, K, 2022) |
| "Rosacea is a chronic skin disorder involving central facial erythema secondary to vascular instability and cutaneous inflammation." | 3.01 | Neurogenic Rosacea Treatment: A Literature Review. ( Gold, MH; Ivanic, MG; Javadi, SS; Norden, A; Oulee, A; Wu, JJ, 2023) |
| "Metronidazole was used in 14% of patients (n = 19/135), with a complete response being reported in 79% (n = 15/19) and partial response in 21% (n = 4/19)." | 3.01 | Treatment of pediatric ocular rosacea: A systematic review. ( Avraham, S; Kashetsky, N; Khaslavsky, S; Mukovozov, I; Starkey, SY, 2023) |
| "Background: Rosacea is characterized by irritation associated with erythema, telangiectasias and papules/pustules." | 2.90 | Natural Skin Care Products as Adjunctive to Prescription Therapy in Moderate to Severe Rosacea ( Draelos, ZD; Gunt, H; Levy, SB, 2019) |
| "Rosacea is a chronic and relapsing facial dermatosis that encompasses a wide spectrum of clinical phenotypes (transient/persistent erythema, telangiectasias, papules/pustules, edema, phymatous changes, and ocular symptoms) often with uncomfortable symptoms such as flushing, pain, burning, edema, and dryness." | 2.82 | Advances in pharmacotherapy for rosacea: what is the current state of the art? ( Dall'Oglio, F; Gerbino, C; Micali, G; Nasca, MR, 2022) |
| "Numerous methods for the treatment of rosacea are defined by the diversity of etiologic and pathogenic factors of dermatosis, its stage and clinical form." | 2.79 | [Angioprotectors in the treatment of rosacea]. ( Katsitadze, A; Tchitanava, L; Tsiskarishvili, NI; Tsiskarishvili, NV; Tsiskarishvili, Ts, 2014) |
| "Rosacea is a chronic skin disease of unknown etiology, affecting the central areas of the face skin (cheeks, chin, nose, forehead) and is characterized by periods of remission and exacerbation." | 2.78 | [New possibilities in the treatment of early stages of rosacea]. ( Katsitadze, A; Tsiskarishvili, NV; Tsiskarishvili, Ts, 2013) |
| "Rosacea is a leading reason why people seek the care of a dermatologist, accounting for nearly 7 million office visits annually." | 2.75 | Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. ( Bruce, S; Del Rosso, JQ; Jarratt, M; Menter, A; Staedtler, G, 2010) |
| " Only 7% of participants had treatment-related adverse events (AEs), mostly mild or moderate in severity." | 2.75 | Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial. ( Del Rosso, JQ, 2010) |
| "Azelaic acid cream was significantly more effective on inflammatory lesions but not erythema than the other two creams." | 2.74 | Comparative study of some treatment modalities of rosacea. ( Abdel Gawad, EH; Al Mokadem, S; El Harras, MA; Gomaa, SM; Mostafa, FF; Nassar, AA, 2009) |
| "Rosacea is a common and chronic disorder characterized by flushing, erythema, papules, pustules, and telangiectasia on the central part of the face." | 2.73 | Beneficial use of Cetaphil moisturizing cream as part of a daily skin care regimen for individuals with rosacea. ( Baltas, E; Czernielewski, J; Laquieze, S, 2007) |
| "Effective treatments for rosacea, including topical metronidazole and systemic antibiotics, have anti-inflammatory activity, which may be more important than their antimicrobial activity in this setting." | 2.73 | Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. ( Fowler, JF, 2007) |
| "Rosacea is an inflammatory dermatologic disorder characterized by the presence of facial erythema, visible blood vessels, papules, and pustules." | 2.72 | Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. ( Arsonnaud, S; Kerrouche, N; Wolf, JE, 2006) |
| "Rosacea is a common, recurrent, inflammatory dermatologic disorder characterized by the presence of facial erythema, visible blood vessels, papules, and pustules." | 2.72 | A look at the safety of metronidazole 1% gel: cumulative irritation, contact sensitization, phototoxicity, and photoallergy potential. ( Beutner, KR; Calvarese, B; Lemke, S, 2006) |
| "Metronidazole 1% gel is a clear gel that exhibits advantageous qualities." | 2.72 | A novel aqueous metronidazole 1% gel with hydrosolubilizing agents (HSA-3). ( Basu, S; Dow, G, 2006) |
| "After eradication, 51 out of 53 treated rosacea patients became Hp negative." | 2.69 | Helicobacter pylori and its eradication in rosacea. ( Bielański, W; Karczewska, E; Konturek, SJ; Pytko-Polonczyk, J; Sliwowski, Z; Szlachcic, A, 1999) |
| "Acne rosacea is a common skin condition characterized by flushing episodes, erythema, telangiectasia, and recurrent crops of inflammatory papules and pustules that involve the face in a symmetrical distribution." | 2.68 | A pilot study of 5 percent permethrin cream versus 0.75 percent metronidazole gel in acne rosacea. ( Signore, RJ, 1995) |
| "Papulopustular rosacea is characterized by papules and pustules in the central facial region." | 2.58 | A Review of the Current Modalities for the Treatment of Papulopustular Rosacea. ( Alinia, H; Feldman, SR; Fleischer, A; McGregor, SP; Snyder, A; Tuchayi, SM, 2018) |
| "Rosacea is a chronic facial inflammatory dermatosis characterized by background facial erythema and flushing and may be accompanied by inflammatory papules and pustules, cutaneous fibrosis and hyperplasia known as phyma, and ocular involvement." | 2.53 | Canadian Clinical Practice Guidelines for Rosacea. ( Asai, Y; Baibergenova, A; Barankin, B; Cochrane, CL; Humphrey, S; Lynde, CW; Marcoux, D; Poulin, Y; Rivers, JK; Sapijaszko, M; Sibbald, RG; Tan, J; Toole, J; Ulmer, M; Zip, C, 2016) |
| "Rosacea is an inflammatory condition of the skin, primarily affecting the central convexities of the face." | 2.53 | Topical and oral therapeutic approach to rosacea. ( Helfrich, YR; Maier, LM, 2016) |
| " At present, subantimicrobial dosing of a tetracycline agent that also maintains anti-inflammatory activity has only been established with doxycycline." | 2.48 | Optimal management of papulopustular rosacea: rationale for combination therapy. ( Bhatia, ND; Del Rosso, JQ, 2012) |
| "A number of therapies are available to treat rosacea, some of which can be used in combination." | 2.46 | A review of the diagnosis and treatment of rosacea. ( Berk, T; Scheinfeld, N, 2010) |
| "Metronidazole is a synthetic nitroimidazole derivative with antimicrobial and antiinflammatory properties." | 2.46 | Innovative use of topical metronidazole. ( Zip, CM, 2010) |
| "Rosacea is one of the most common chronic dermatological diseases." | 2.46 | [Rosacea: pathogenesis, clinical forms and therapy]. ( Kárpáti, S; Preisz, K, 2010) |
| " Further interesting therapy options for the short- and long-term therapy of rosacea could be low-dose minocycline and isotretinoin; however, too little data are available with regard to the effectiveness, safety, optimal dosage and appropriate length of treatment for these medications to draw final conclusions." | 2.45 | Current topical and systemic approaches to treatment of rosacea. ( Korting, HC; Schöllmann, C, 2009) |
| "There are many options for the treatment of acne rosacea, including topical and systemic therapies, laser and light-based therapies, and surgical procedures." | 2.45 | Updates on the pathophysiology and management of acne rosacea. ( Choudhary, S; Elsaie, ML, 2009) |
| "Rosacea is a common chronic skin and ocular condition." | 2.44 | Systematic review of rosacea treatments. ( Gover, MD; Graber, M; Gupta, AK; Hollis, S; van Zuuren, EJ, 2007) |
| "Because rosacea is a chronic condition, pharmacologic maintenance therapy is necessary to maintain remission." | 2.43 | Present and future rosacea therapy. ( Wolf, JE, 2005) |
| "The 3 primary agents for the topical treatment of rosacea are metronidazole, azelaic acid, and sodium sulfacetamide-sulfur." | 2.43 | Topical therapies for rosacea. ( Berson, DS; Nally, JB, 2006) |
| "Rosacea is a very common facial dermatosis." | 2.42 | Medical treatment of rosacea with emphasis on topical therapies. ( Del Rosso, JQ, 2004) |
| "Metronidazole was the first topical therapy approved for rosacea and is still considered the foundation therapy by many researchers and dermatologists." | 2.42 | The role of topical metronidazole in the treatment of rosacea. ( Wolf, JE, 2004) |
| "Rosacea is a chronic, cutaneous vascular disorder that affects approximately 13 million Americans." | 2.41 | Identifying and treating rosacea. ( Cuevas, T, 2001) |
| "Rosacea is relatively common, typically occurring in individuals of Northern European and Celtic origin between 30 and 50 years of age." | 2.41 | Topical metronidazole for rosacea. ( Chaudhry, M; Gupta, AK, 2002) |
| "Rosacea is an age-related disorder of the central portion of the facial skin whose peak onset occurs in persons in their 40s and 50s." | 2.40 | Rosacea: how to recognize and treat an age-related skin disease. ( Litt, JZ, 1997) |
| "pylori infection." | 2.39 | May Helicobacter pylori be important for dermatologists? ( Drago, F; Parodi, A; Rebora, A, 1995) |
| "For the treatment of rosacea, the interdisciplinary guideline committee, with representatives of the German Dermatological Society (DDG), the Professional Association of German Dermatologists (BVDD), the German Opthalmological Society (DOG), the Society for Dermopharmacy (GD), the Swiss Society for Dermatology and Venereology (SGDV) and the German Rosacea Aid e." | 1.72 | S2k guideline: Rosacea. ( Bernhard, D; Clanner-Engelshofen, BM; Dargatz, S; Flaig, MJ; Gieler, U; Kinberger, M; Klövekorn, W; Kuna, AC; Läuchli, S; Lehmann, P; Nast, A; Pleyer, U; Reinholz, M; Schaller, M; Schöfer, H; Schwennesen, T; Steinhoff, M; Werner, RN; Zierhut, M, 2022) |
| "Rosacea is a common cutaneous condition affecting predominantly the face." | 1.62 | Rosacea. ( Al-Niaimi, F; Ali, FR; Searle, T, 2021) |
| "Nowadays, a wide range of treatments for rosacea is available: topical metronidazole, oral metronidazole, topical ivermectin, oral tetracyclines, oral isotretinoin, systemic steroids, photodynamic therapy, or pulsed dye laser." | 1.56 | Use of permethrin in the treatment of rosacea fulminans during pregnancy: One case report. ( Aguado García, Á; Garabito Solovera, E; Garayar Cantero, M; Manchado López, P; Ruiz Sánchez, D; Valtueña, J, 2020) |
| "Rosacea is a common chronic facial skin disease." | 1.48 | Clinical characteristics and management of patients with rosacea in a tertiary dermatology center in Singapore from 2009 to 2013. ( Chan, R; Cheong, KW; Lai, YC; Yew, YW, 2018) |
| "Rosacea is a chronic and common cutaneous condition characterised by symptoms of facial flushing and a broad spectrum of clinical signs." | 1.46 | Rosacea. ( Chong, AH; Maor, D, 2017) |
| "Granulomatous rosacea is a rare chronic inflammatory skin disease with an unknown origin." | 1.46 | Granulomatous rosacea: a case report. ( Kelati, A; Mernissi, FZ, 2017) |
| "Papulopustular rosacea is a chronic skin disease involving central facial erythema in combination with papules and pustules." | 1.43 | Cost-Effectiveness of Ivermectin 1% Cream in Adults with Papulopustular Rosacea in the United States. ( Bertranou, E; Dansk, V; Feldman, SR; Stein Gold, L; Taieb, A, 2016) |
| "Rosacea is a chronic inflammatory disease that can manifest as a spectrum of symptoms including erythema, inflammatory lesions, edema, and telangiectasia." | 1.43 | A Tailored Approach to the Treatment of a Patient with a Severe Dynamic Manifestation of Rosacea: A Case Report. ( Gonser, L; Schaller, M, 2016) |
| "Rosacea is a chronic facial skin condition of unknown cause." | 1.42 | Rosacea: Diagnosis and Treatment. ( Muncie, HL; Oge', LK; Phillips-Savoy, AR, 2015) |
| "Rosacea is a chronic facial skin disease that mainly occurs in people aged over 30 years." | 1.42 | Ivermectin cream for rosacea. ( , 2015) |
| "Improved strategies to reach untreated people with rosacea are needed." | 1.40 | Patterns of ambulatory care usage and leading treatments for rosacea. ( Davis, SA; Feldman, SR, 2014) |
| "Acne vulgaris is a pervasive inflammatory disorder of the skin, with multiple etiologies and treatment options." | 1.40 | Acne vulgaris in the context of complex medical co-morbities: the management of severe acne vulgaris in a female with retinitis pigmentosa - utilizing pulse dye laser in conjunction with medical therapy. ( Keck, L; Shariff, A; Zlotoff, B, 2014) |
| "Rosacea is a common dermatosis that can involve the bald area of the scalp." | 1.38 | [Acantholytic rosacea of the forehead and scalp in a patient with Hailey-Hailey disease]. ( Cribier, B; Kanter, P; Lipsker, D; Mohr, M, 2012) |
| "Rosacea is a common chronic skin disorder that has significant impact on the self-esteem and quality of life of affected individuals." | 1.38 | Rosacea: update on management and emerging therapies. ( Fallen, RS; Gooderham, M, 2012) |
| "Metronidazole is an effective antibiotic in the treatment of moderate-to severe rosacea." | 1.37 | Evaluation of mechanical and rheological properties of metronidazole gel as local delivery system. ( Jelvehgari, M; Montazam, H, 2011) |
| "Many options exist for the treatment of rosacea, including topical and systemic therapies, laser and light-based therapies, and surgical procedures." | 1.35 | Rosacea and its topical management. ( Gooderham, M, 2009) |
| "Metronidazole has been the first-line topical agent therapy for many years; nevertheless the mechanism of action is still not well understood." | 1.34 | Scavenging properties of metronidazole on free oxygen radicals in a skin lipid model system. ( Getie, M; Hünerbein, A; Jäckel, A; Narayanan, S; Neubert, RH, 2007) |
| "Rosacea is a common, chronic facial dermatosis that may present in varying manners." | 1.33 | Diagnosing and managing the patient with rosacea. ( Mackley, CL; Thiboutot, DM, 2005) |
| "Rosacea is a common dermatosis affecting the central portion of the face." | 1.31 | Women commonly seek care for rosacea: dermatologists frequently provide the care. ( Feldman, SR; Fleischer, AB; Gupta, AK; Hollar, CB, 2001) |
| "Rosacea is an inflammatory disease of the face and eyes." | 1.31 | Treatment of rosacea. ( Webster, GF, 2001) |
| "Treatment with clarithromycin, metronidazole and pantoprazole eradicated H." | 1.31 | Resolution of granulomatous rosacea after eradication of Helicobacter pylori with clarithromycin, metronidazole and pantoprazole. ( Kaddu, S; Kränke, B; Mayr-Kanhäuser, S; Müllegger, RR, 2001) |
| "Rosacea is a skin dysfunction affecting a large number of individuals." | 1.28 | Management of rosacea. ( Sober, AJ, 1992) |
| "The orphan product, MetroGel, for the treatment of rosacea, required approximately five years of development before it was approved for marketing by the Food and Drug Administration." | 1.28 | Development of an orphan drug by a start-up company. MetroGel for rosacea. ( Borgman, RJ, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 44 (18.88) | 18.7374 |
| 1990's | 28 (12.02) | 18.2507 |
| 2000's | 73 (31.33) | 29.6817 |
| 2010's | 66 (28.33) | 24.3611 |
| 2020's | 22 (9.44) | 2.80 |
| Authors | Studies |
|---|---|
| Miyachi, Y | 3 |
| Yamasaki, K | 2 |
| Fujita, T | 1 |
| Fujii, C | 1 |
| Clanner-Engelshofen, BM | 1 |
| Bernhard, D | 1 |
| Dargatz, S | 1 |
| Flaig, MJ | 1 |
| Gieler, U | 1 |
| Kinberger, M | 1 |
| Klövekorn, W | 1 |
| Kuna, AC | 1 |
| Läuchli, S | 1 |
| Lehmann, P | 1 |
| Nast, A | 1 |
| Pleyer, U | 1 |
| Schaller, M | 4 |
| Schöfer, H | 2 |
| Steinhoff, M | 1 |
| Schwennesen, T | 1 |
| Werner, RN | 1 |
| Zierhut, M | 1 |
| Reinholz, M | 1 |
| Saka Dwipayanti, K | 1 |
| Azhar, M | 1 |
| Rahman, L | 1 |
| Pakki, E | 1 |
| Himawan, A | 1 |
| Permana, AD | 1 |
| Yeh, MC | 1 |
| Tsai, J | 1 |
| Huang, YC | 1 |
| Wang, HH | 1 |
| Dall'Oglio, F | 1 |
| Nasca, MR | 1 |
| Gerbino, C | 1 |
| Micali, G | 1 |
| Abramovits, W | 1 |
| Jessu, R | 1 |
| Vincent, KD | 1 |
| Gupta, AK | 4 |
| Li, S | 1 |
| Zhao, X | 1 |
| Chen, Y | 1 |
| Liu, J | 1 |
| Ivanic, MG | 1 |
| Oulee, A | 1 |
| Norden, A | 1 |
| Javadi, SS | 1 |
| Gold, MH | 1 |
| Wu, JJ | 1 |
| Kazemi, S | 1 |
| Hawkes, JE | 1 |
| Khaslavsky, S | 1 |
| Starkey, SY | 1 |
| Avraham, S | 1 |
| Kashetsky, N | 1 |
| Mukovozov, I | 1 |
| Ansorge, C | 1 |
| Technau-Hafsi, K | 1 |
| Jacob, S | 1 |
| VanDaele, MA | 1 |
| Brown, JN | 1 |
| Fritsch, P | 1 |
| Kolber, MR | 1 |
| Korownyk, C | 1 |
| Torregrosa, A | 1 |
| Ochoa-Andrade, AT | 1 |
| Parente, ME | 1 |
| Vidarte, A | 1 |
| Guarinoni, G | 1 |
| Savio, E | 1 |
| Garayar Cantero, M | 1 |
| Garabito Solovera, E | 1 |
| Aguado García, Á | 1 |
| Valtueña, J | 1 |
| Ruiz Sánchez, D | 1 |
| Manchado López, P | 1 |
| Williamson, T | 1 |
| LaRose, A | 1 |
| Cameron, J | 1 |
| Lott, J | 1 |
| Eaddy, M | 1 |
| Hopson, S | 1 |
| Shih, HC | 1 |
| Tennant, LT | 1 |
| Bustos, R | 1 |
| Cortes, A | 1 |
| McNab, ME | 1 |
| Fuentes, E | 1 |
| Castro, A | 1 |
| Wortsman, X | 1 |
| Baghad, B | 1 |
| El Fatoiki, FZ | 1 |
| Benhsaien, I | 1 |
| Bousfiha, AA | 1 |
| Puel, A | 1 |
| Migaud, M | 1 |
| Chiheb, S | 1 |
| Ailal, F | 1 |
| Hedberg, ML | 1 |
| Chibnall, RJ | 1 |
| Compton, LA | 1 |
| Searle, T | 1 |
| Al-Niaimi, F | 1 |
| Ali, FR | 1 |
| Kang, CN | 1 |
| Shah, M | 1 |
| Tan, J | 3 |
| Gomolin, T | 1 |
| Cline, A | 1 |
| Pereira, F | 1 |
| Maor, D | 1 |
| Chong, AH | 1 |
| Webster, G | 5 |
| Jackson, JM | 1 |
| Kerrouche, N | 2 |
| Schäfer, G | 1 |
| Kelati, A | 1 |
| Mernissi, FZ | 1 |
| Braun, SA | 1 |
| Gerber, PA | 1 |
| Cheong, KW | 1 |
| Yew, YW | 1 |
| Lai, YC | 1 |
| Chan, R | 1 |
| McGregor, SP | 1 |
| Alinia, H | 1 |
| Snyder, A | 1 |
| Tuchayi, SM | 1 |
| Fleischer, A | 2 |
| Feldman, SR | 8 |
| McGee, JS | 1 |
| Wilkin, JK | 2 |
| Lev-Tov, H | 1 |
| Rill, JS | 1 |
| Liu, G | 1 |
| Kirby, JS | 1 |
| Shinde, UA | 1 |
| Parmar, SJ | 1 |
| Easwaran, S | 1 |
| Draelos, ZD | 3 |
| Gunt, H | 1 |
| Levy, SB | 1 |
| Prieto Herman Reinehr, C | 1 |
| Kalil, CLPV | 1 |
| Bakos, RM | 1 |
| Salleras, M | 1 |
| Alegre, M | 1 |
| Alonso-Usero, V | 1 |
| Boixeda, P | 1 |
| Domínguez-Silva, J | 1 |
| Fernández-Herrera, J | 1 |
| García-Navarro, X | 1 |
| Jiménez, N | 1 |
| Llamas, M | 1 |
| Nadal, C | 1 |
| Del Pozo-Losada, J | 1 |
| Querol, I | 1 |
| Salgüero, I | 1 |
| Soto de Delás, J | 1 |
| Wang, GJ | 1 |
| Gao, XY | 1 |
| Wu, Y | 1 |
| He, HQ | 1 |
| Yu, Y | 1 |
| Qin, HH | 1 |
| Shen, WT | 1 |
| Del Rosso, JQ | 13 |
| Gallo, RL | 1 |
| Tanghetti, E | 2 |
| Thiboutot, D | 4 |
| Seite, S | 1 |
| Benech, F | 1 |
| Berdah, S | 1 |
| Bayer, M | 1 |
| Veyrat, S | 1 |
| Segot, E | 1 |
| Sakalikova, M | 1 |
| Gibejova, L | 1 |
| Zelenkova, H | 1 |
| Davis, SA | 1 |
| Shariff, A | 1 |
| Keck, L | 1 |
| Zlotoff, B | 1 |
| Yu, M | 1 |
| Ma, H | 1 |
| Lei, M | 1 |
| Li, N | 1 |
| Tan, F | 1 |
| Gallo, R | 3 |
| Eichenfield, LF | 1 |
| Stein-Gold, L | 1 |
| Berson, D | 1 |
| Zaenglein, A | 1 |
| Tsiskarishvili, NV | 2 |
| Katsitadze, A | 2 |
| Tsiskarishvili, Ts | 2 |
| Tchitanava, L | 1 |
| Tsiskarishvili, NI | 1 |
| Veraldi, S | 1 |
| Raia, DD | 1 |
| Schianchi, R | 1 |
| De Micheli, P | 1 |
| Barbareschi, M | 1 |
| Taieb, A | 6 |
| Ortonne, JP | 1 |
| Ruzicka, T | 4 |
| Roszkiewicz, J | 1 |
| Berth-Jones, J | 3 |
| Peirone, MH | 1 |
| Jacovella, J | 3 |
| Kircik, LH | 1 |
| Sattler, EC | 1 |
| Hoffmann, VS | 1 |
| Braunmühl, TV | 1 |
| Berking, C | 1 |
| van Zuuren, EJ | 4 |
| Fedorowicz, Z | 2 |
| Carter, B | 2 |
| van der Linden, MM | 1 |
| Charland, L | 1 |
| Faghihi, G | 1 |
| Khosravani, P | 1 |
| Nilforoushzadeh, MA | 1 |
| Hosseini, SM | 1 |
| Assaf, F | 1 |
| Zeinali, N | 1 |
| Smiley, A | 1 |
| Lee, GL | 1 |
| Zirwas, MJ | 1 |
| Deeks, ED | 1 |
| Oge', LK | 1 |
| Muncie, HL | 1 |
| Phillips-Savoy, AR | 1 |
| Khemis, A | 1 |
| Barańska-Rybak, W | 1 |
| Schauber, J | 1 |
| Briantais, P | 1 |
| Passeron, T | 2 |
| Lo Schiavo, A | 1 |
| Tirri, R | 1 |
| Peccerillo, F | 1 |
| Abbondanza, C | 1 |
| Russo, B | 1 |
| Caccavale, S | 1 |
| Huang, MY | 1 |
| Wertheimer, A | 1 |
| Asai, Y | 1 |
| Baibergenova, A | 1 |
| Barankin, B | 1 |
| Cochrane, CL | 1 |
| Humphrey, S | 1 |
| Lynde, CW | 1 |
| Marcoux, D | 1 |
| Poulin, Y | 1 |
| Rivers, JK | 1 |
| Sapijaszko, M | 1 |
| Sibbald, RG | 1 |
| Toole, J | 1 |
| Ulmer, M | 1 |
| Zip, C | 2 |
| Stein Gold, L | 1 |
| Dansk, V | 1 |
| Bertranou, E | 1 |
| Dirschka, T | 1 |
| Schmitz, L | 1 |
| Bartha, Á | 1 |
| Helfrich, YR | 1 |
| Maier, LM | 1 |
| Gonser, L | 1 |
| Schlessinger, J | 1 |
| Werschler, P | 1 |
| Mostafa, FF | 1 |
| El Harras, MA | 1 |
| Gomaa, SM | 1 |
| Al Mokadem, S | 1 |
| Nassar, AA | 1 |
| Abdel Gawad, EH | 1 |
| Thomas, K | 1 |
| Yelverton, CB | 3 |
| Yentzer, BA | 1 |
| Balkrishnan, R | 3 |
| Fleischer, AB | 6 |
| Fernández-Jorge, B | 1 |
| Goday Buján, J | 1 |
| Fernández-Torres, R | 1 |
| Rodríguez-Lojo, R | 1 |
| Fonseca, E | 1 |
| Larios, G | 1 |
| Alevizos, A | 1 |
| Perimeni, D | 1 |
| Rigopoulos, D | 1 |
| Katsambas, A | 2 |
| Jayawant, SS | 1 |
| Camacho, FT | 2 |
| Yentzer, B | 1 |
| Madsen, JT | 2 |
| Lorentzen, HF | 1 |
| Paulsen, E | 1 |
| Gooderham, M | 2 |
| Korting, HC | 2 |
| Schöllmann, C | 1 |
| Koca, R | 2 |
| Altinyazar, HC | 2 |
| Ankarali, H | 1 |
| Muhtar, S | 1 |
| Tekin, NS | 2 |
| Cinar, S | 1 |
| Elsaie, ML | 1 |
| Choudhary, S | 1 |
| Rosmaninho, A | 1 |
| Alves, R | 1 |
| Lima, M | 1 |
| Lobo, I | 1 |
| Amorim, I | 1 |
| Selores, M | 1 |
| Gross, H | 1 |
| Scheinfeld, N | 1 |
| Berk, T | 1 |
| Nikolaou, V | 1 |
| Stratigos, A | 1 |
| Antoniou, C | 1 |
| Kiagia, M | 1 |
| Nikolaou, C | 1 |
| Syrigos, K | 1 |
| Zip, CM | 1 |
| Bruce, S | 1 |
| Jarratt, M | 3 |
| Menter, A | 1 |
| Staedtler, G | 1 |
| Preisz, K | 1 |
| Kárpáti, S | 1 |
| Serdar, ZA | 1 |
| Yaşar, Ş | 1 |
| May, D | 1 |
| Kelsberg, G | 1 |
| Safranek, S | 1 |
| Kramer, S | 1 |
| Graber, MA | 2 |
| Colón, LE | 2 |
| Preston, N | 1 |
| Johnson, LA | 2 |
| Gottschalk, RW | 2 |
| Jelvehgari, M | 1 |
| Montazam, H | 1 |
| Léoni, S | 1 |
| Mesplié, N | 1 |
| Aitali, F | 2 |
| Chamaillard, M | 2 |
| Boralevi, F | 2 |
| Marques da Costa, C | 2 |
| Léauté-Labrèze, C | 2 |
| Colin, J | 1 |
| Mortemousque, B | 2 |
| Parodi, A | 3 |
| Drago, F | 5 |
| Paolino, S | 2 |
| Cozzani, E | 2 |
| Leyden, JJ | 1 |
| Tirnaksiz, F | 1 |
| Kayiş, A | 1 |
| Çelebi, N | 1 |
| Adişen, E | 1 |
| Erel, A | 1 |
| Bhatia, ND | 1 |
| Subashini, K | 1 |
| Pushpa, G | 1 |
| Venugopal, V | 1 |
| Murali, N | 1 |
| Mohr, M | 1 |
| Kanter, P | 1 |
| Cribier, B | 1 |
| Lipsker, D | 1 |
| Fallen, RS | 1 |
| Koçak, M | 1 |
| Yağli, S | 1 |
| Vahapoğlu, G | 1 |
| Ekşioğlu, M | 1 |
| Swenor, ME | 1 |
| Fuchs, SS | 1 |
| Wolf, R | 2 |
| Orion, E | 1 |
| Matz, H | 1 |
| Elewski, BE | 4 |
| Pariser, DM | 1 |
| Wolf, JE | 6 |
| Leyden, J | 1 |
| Millikan, LE | 3 |
| Odom, RB | 2 |
| Shalita, A | 1 |
| Czernielewski, J | 2 |
| Liu, Y | 1 |
| Oztürkcan, S | 1 |
| Ermertcan, AT | 1 |
| Sahin, MT | 1 |
| Afşar, FS | 1 |
| Jones, D | 1 |
| Lindow, KB | 1 |
| Eştürk, E | 1 |
| Mackley, CL | 1 |
| Thiboutot, DM | 2 |
| Torok, HM | 1 |
| Dunlap, FE | 1 |
| Egan, N | 1 |
| Stewart, D | 2 |
| Roebuck, HL | 1 |
| Sanchez, J | 1 |
| Somolinos, AL | 1 |
| Almodóvar, PI | 1 |
| Bradshaw, M | 1 |
| Powala, C | 1 |
| Nally, JB | 1 |
| Berson, DS | 1 |
| Elewski, B | 1 |
| Kirkland, CR | 1 |
| Ferahbas, A | 1 |
| Utas, S | 2 |
| Mistik, S | 1 |
| Uksal, U | 1 |
| Peker, D | 1 |
| Schulz, H | 1 |
| Yoo, J | 1 |
| Reid, DC | 1 |
| Kimball, AB | 1 |
| Arsonnaud, S | 1 |
| Beutner, KR | 1 |
| Lemke, S | 1 |
| Calvarese, B | 1 |
| Dow, G | 1 |
| Basu, S | 1 |
| Schmutz, JL | 1 |
| Weber, TM | 1 |
| Ceilley, RI | 1 |
| Buerger, A | 1 |
| Kolbe, L | 1 |
| Trookman, NS | 1 |
| Rizer, RL | 1 |
| Schoelermann, A | 1 |
| Gover, MD | 1 |
| Graber, M | 1 |
| Hollis, S | 1 |
| Baum, EW | 1 |
| Kakita, LS | 1 |
| Laquieze, S | 1 |
| Baltas, E | 1 |
| Thormann, J | 1 |
| Kerre, S | 1 |
| Andersen, KE | 1 |
| Goossens, A | 1 |
| Musial, W | 1 |
| Fowler, JF | 1 |
| Conde, JF | 1 |
| Narayanan, S | 1 |
| Hünerbein, A | 1 |
| Getie, M | 1 |
| Jäckel, A | 1 |
| Neubert, RH | 1 |
| Pariser, D | 1 |
| Levine, N | 1 |
| Persi, A | 1 |
| Rebora, A | 4 |
| Babaiants, RS | 1 |
| Il'inskaia, AV | 1 |
| Gromova, SA | 1 |
| Samgin, MA | 1 |
| Iastrebova, RI | 1 |
| Nielsen, PG | 3 |
| Rubisz-Brzezińska, J | 1 |
| Zebracka, T | 1 |
| Brzezińska-Wcisło, L | 1 |
| Kralewska, W | 1 |
| Döring, HF | 2 |
| Ilgner, M | 2 |
| Aitken, G | 1 |
| Braun-Falco, O | 1 |
| Meynadier, J | 4 |
| Guilhou, JJ | 4 |
| Lipets, ME | 1 |
| Prokof'eva, NM | 1 |
| Shibaeva, LN | 1 |
| Razina, LG | 1 |
| Glukhen'kiĭ, BT | 2 |
| Snitsanenko, OV | 1 |
| Prinz, L | 1 |
| Kürkçüoğlu, N | 1 |
| Atakan, N | 1 |
| Dupont, C | 1 |
| Saihan, EM | 1 |
| Burton, JL | 2 |
| Dovzhanskiĭ, SI | 1 |
| Grashkina, IG | 1 |
| Iaksanova, EM | 1 |
| Smeral, R | 1 |
| Dubán, S | 1 |
| Zhilina, VG | 1 |
| Skorobogatova, VV | 1 |
| Bazyka, AP | 1 |
| Hoekzema, R | 1 |
| Hulsebosch, HJ | 1 |
| Bos, JD | 1 |
| Hogan, DJ | 1 |
| Picciotto, A | 1 |
| Espagne, E | 1 |
| Guillaume, JC | 1 |
| Archimbaud, A | 1 |
| Baspeyras, M | 1 |
| Boitier, F | 1 |
| Bussière, M | 1 |
| Chamberlin, J | 1 |
| Coin, A | 1 |
| Di Crescenzo, MC | 1 |
| Dolivo, M | 1 |
| Signore, RJ | 1 |
| Barrio, J | 1 |
| Lecona, M | 1 |
| Hernanz, JM | 1 |
| Sánchez, M | 1 |
| Gurbindo, MD | 1 |
| Lázaro, P | 1 |
| Barrio, JL | 1 |
| Barnhorst, DA | 1 |
| Foster, JA | 1 |
| Chern, KC | 1 |
| Meisler, DM | 1 |
| Litt, JZ | 1 |
| Breneman, DL | 1 |
| Hevia, O | 1 |
| Hino, PD | 1 |
| Drake, LA | 1 |
| Cohen, PR | 1 |
| Dahl, MV | 2 |
| Katz, HI | 1 |
| Krueger, GG | 1 |
| Parker, F | 2 |
| Aly, R | 1 |
| Bayles, C | 1 |
| Reusser, B | 1 |
| Weidner, M | 1 |
| Coleman, E | 1 |
| Patrignelli, R | 1 |
| Tuley, MR | 2 |
| Baker, MO | 1 |
| Herndon, JH | 1 |
| Czernielewski, JM | 1 |
| Jorizzo, JL | 1 |
| Lebwohl, M | 1 |
| Tobey, RE | 1 |
| Junk, AK | 1 |
| Lukacs, A | 1 |
| Kampik, A | 1 |
| Ozbakir, O | 1 |
| Turasan, A | 1 |
| Utaş, C | 1 |
| Maddin, S | 1 |
| Shear, NH | 1 |
| Levine, C | 1 |
| Grossmann, B | 1 |
| Jung, K | 1 |
| Linse, R | 1 |
| Grilli, R | 1 |
| Hirschmann, JV | 1 |
| Szlachcic, A | 1 |
| Sliwowski, Z | 1 |
| Karczewska, E | 1 |
| Bielański, W | 1 |
| Pytko-Polonczyk, J | 1 |
| Konturek, SJ | 1 |
| Silver, EA | 1 |
| Silver, AH | 1 |
| Silver, DS | 1 |
| Cuevas, T | 1 |
| Tan, JK | 1 |
| Hollar, CB | 1 |
| Webster, GF | 1 |
| Kaplan, D | 1 |
| Baker, MD | 1 |
| Mayr-Kanhäuser, S | 1 |
| Kränke, B | 1 |
| Kaddu, S | 1 |
| Müllegger, RR | 1 |
| Chaudhry, M | 1 |
| Baima, B | 1 |
| Sticherling, M | 1 |
| Pye, RJ | 1 |
| Braun, W | 1 |
| Koester, H | 1 |
| Taube, KM | 1 |
| Guilhou, E | 2 |
| Malbos, S | 2 |
| Lauret, P | 1 |
| Boullie, MC | 1 |
| Bravard, P | 1 |
| Stieger, M | 1 |
| Sober, AJ | 2 |
| Borgman, RJ | 1 |
| Schmadel, LK | 1 |
| McEvoy, GK | 1 |
| Tur, E | 1 |
| Ryatt, KS | 1 |
| Maibach, HI | 1 |
| Akamatsu, H | 1 |
| Oguchi, M | 1 |
| Nishijima, S | 1 |
| Asada, Y | 1 |
| Takahashi, M | 1 |
| Ushijima, T | 1 |
| Niwa, Y | 2 |
| Goldsmith, MF | 1 |
| Lowe, NJ | 1 |
| Henderson, T | 1 |
| Smith, S | 1 |
| Turk, K | 1 |
| Bourrel, M | 1 |
| Shelley, WB | 1 |
| Shelley, ED | 1 |
| Burmeister, V | 1 |
| Bjerke, JR | 1 |
| Snitsarenko, OV | 1 |
| Imamura, S | 1 |
| Veien, NK | 2 |
| Christiansen, JV | 1 |
| Hjorth, N | 1 |
| Schmidt, H | 1 |
| Aronson, IK | 1 |
| Rumsfield, JA | 1 |
| West, DP | 1 |
| Alexander, J | 1 |
| Fischer, JH | 1 |
| Paloucek, FP | 1 |
| Bleicher, PA | 1 |
| Charles, JH | 1 |
| Grosshans, E | 1 |
| Shakhnes, IE | 1 |
| Krepker, IaB | 1 |
| Nasir, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Suitability of Two Skin Care Regimens in Moderate to Severe Facial Rosacea[NCT03392558] | 80 participants (Actual) | Interventional | 2018-01-01 | Completed | |||
| Potassium Titanyl Phosphate Laser Versus Pulsed Dye Laser for Rosacea - a Prospective Case-Control Study[NCT05771298] | 30 participants (Anticipated) | Interventional | 2023-02-01 | Recruiting | |||
| Topical Brimonidine Reduces IPL-induced Erythema Without Affecting Efficacy: a Randomized Controlled Trial in Patients With Facial Telangiectasias[NCT02761174] | Phase 4 | 19 participants (Actual) | Interventional | 2016-03-13 | Completed | ||
| ORBS: Ocular Rosacea Biome Study[NCT05296837] | Phase 4 | 50 participants (Anticipated) | Interventional | 2023-06-22 | Recruiting | ||
| An Exploratory, Multicenter, Investigator-blinded, Active-controlled Study to Investigate the Efficacy of Topical Azelaic Acid (AzA)15% Gel Twice Daily or Metronidazole Topical Gel 1% Once Daily, Plus Anti-inflammatory Dose Doxycycline (40mg) Once Daily i[NCT00855595] | Phase 4 | 207 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%[NCT00668655] | 30 participants (Actual) | Observational | 2008-02-29 | Completed | |||
| "Zinc Sulfate in the Treatment of Rosacea: A Randomized, Controlled Trial. Prospective, Double Blind, Randomized, Controlled Trial Comparing the Effects of Supplemental Zinc Sulfate and Placebo on the Severity of Rosacea."[NCT00395226] | 65 participants (Actual) | Interventional | 2006-07-31 | Terminated (stopped due to Difficulty recruiting subjects) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
NOTE: Negative mean values represent an improvement (decrease of inflammatory lesions) (NCT00855595)
Timeframe: Baseline and Week 2
| Intervention | Inflammatory lesions (Mean) |
|---|---|
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | -10.5 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | -9.4 |
(NCT00855595)
Timeframe: Week 12
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Excellent Improvement | Marked Improvement | Moderate Improvement | No change | Deterioration | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 46.6 | 35.9 | 12.6 | 4.9 | 0 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 42.3 | 34.0 | 17.5 | 6.2 | 0 |
NOTE: Negative mean values represent an improvement (decrease of inflammatory lesions) (NCT00855595)
Timeframe: Baseline and Week 4, 6, 8 and 12
| Intervention | Inflammatory lesions (Mean) | |||
|---|---|---|---|---|
| Week 4 | Week 6 | Week 8 | Week 12 | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | -13.2 | -14.8 | -15.5 | -16.2 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | -12.4 | -14.1 | -15.6 | -16.2 |
(NCT00855595)
Timeframe: Week 2, 4, 6, 8 and 12
| Intervention | Inflammatory lesions (Mean) | ||||
|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 10.1 | 7.4 | 5.9 | 5.1 | 4.4 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 12.5 | 9.5 | 7.8 | 6.4 | 5.7 |
(NCT00855595)
Timeframe: Week 12
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Very Good | Good | Satisfactory | Poor | No Opinion | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 52.0 | 34.3 | 4.9 | 0 | 8.8 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 56.3 | 26.0 | 8.3 | 1.0 | 8.3 |
(NCT00855595)
Timeframe: Week 12
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Excellent | Good | Acceptable despite minor irritation | Less acceptable due to continuous irritation | No opinion | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 53.9 | 34.3 | 7.8 | 2.9 | 1.0 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 72.9 | 15.6 | 11.5 | 0 | 0 |
(NCT00855595)
Timeframe: Week 12
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Excellent Improvement | Good Improvement | Fair Improvement | No Improvement | Worse | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 51.0 | 39.2 | 7.8 | 2.0 | 0 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 49.0 | 33.3 | 15.6 | 1.0 | 1.0 |
NOTE: Negative mean values represent an improvement (decrease of inflammatory lesions) (NCT00855595)
Timeframe: Baseline and Week 2, 4, 6, 8 and 12
| Intervention | Percent of inflammatory lesions (Mean) | ||||
|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | -50.7 | -64.9 | -72.4 | -76.4 | -80.2 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | -43.0 | -56.9 | -64.5 | -71.6 | -75.1 |
(NCT00855595)
Timeframe: Baseline and Weeks 2, 4, 6, 8 and 12
| Intervention | Percentage of participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2, ≥25% improvement | Week 2, ≥50% improvement | Week 2, ≥75% improvement | Week 4, ≥25% improvement | Week 4, ≥50% improvement | Week 4, ≥75% improvement | Week 6, ≥25% improvement | Week 6, ≥50% improvement | Week 6, ≥75% improvement | Week 8, ≥25% improvement | Week 8, ≥50% improvement | Week 8, ≥75% improvement | Week 12, ≥25% improvement | Week 12, ≥50% improvement | Week 12, ≥75% improvement | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 84.9 | 61.3 | 20.8 | 90.6 | 75.5 | 44.3 | 95.3 | 84.9 | 54.7 | 95.3 | 88.7 | 67.0 | 96.2 | 89.6 | 68.9 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 77.2 | 47.5 | 17.8 | 81.2 | 64.4 | 40.6 | 91.1 | 78.2 | 43.6 | 90.1 | 87.1 | 55.4 | 91.1 | 85.1 | 65.3 |
IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information) / Patient response is defined as an IGA score of clear, minimal, or mild (0, 1, or 2) (NCT00855595)
Timeframe: Weeks 2, 4, 6, 8 and 12
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 32.1 | 55.7 | 60.4 | 72.6 | 78.3 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 27.7 | 44.6 | 53.5 | 59.4 | 72.3 |
IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information) / Therapeutic success is defined as an IGA score of clear or minimal (0 or 1). (NCT00855595)
Timeframe: Weeks 2, 4, 6, 8 and 12
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 13.2 | 32.1 | 45.3 | 50.9 | 62.3 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 7.9 | 26.7 | 27.7 | 39.6 | 52.5 |
IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information). (NCT00855595)
Timeframe: At Week 12
| Intervention | Percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 0 - Clear | 1 - Minimal | 2 - Mild | 3 - Mild to moderate | 4 - Moderate | 5 - Moderate to severe | 6 - Severe | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 30.2 | 32.1 | 16.0 | 12.3 | 6.6 | 1.9 | 0.9 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 22.8 | 29.7 | 19.8 | 13.9 | 10.9 | 3.0 | 0 |
IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information). (NCT00855595)
Timeframe: At Week 2
| Intervention | Percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 0 - Clear | 1 - Minimal | 2 - Mild | 3 - Mild to moderate | 4 - Moderate | 5 - Moderate to severe | 6 - Severe | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 0.9 | 12.3 | 18.9 | 33.0 | 25.5 | 9.4 | 0 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 1.0 | 6.9 | 19.8 | 31.7 | 27.7 | 10.9 | 2.0 |
IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information). (NCT00855595)
Timeframe: At Week 4
| Intervention | Percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 0 - Clear | 1 - Minimal | 2 - Mild | 3 - Mild to moderate | 4 - Moderate | 5 - Moderate to severe | 6 - Severe | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 7.5 | 24.5 | 23.6 | 24.5 | 15.1 | 4.7 | 0 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 6.9 | 19.8 | 17.8 | 23.8 | 20.8 | 9.9 | 1.0 |
IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information). (NCT00855595)
Timeframe: At Week 6
| Intervention | Percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 0 - Clear | 1 - Minimal | 2 - Mild | 3 - Mild to moderate | 4 - Moderate | 5 - Moderate to severe | 6 - Severe | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 18.9 | 26.4 | 15.1 | 24.5 | 11.3 | 3.8 | 0 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 9.9 | 17.8 | 25.7 | 19.8 | 19.8 | 6.9 | 0 |
IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information). (NCT00855595)
Timeframe: At Week 8
| Intervention | Percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 0 - Clear | 1 - Minimal | 2 - Mild | 3 - Mild to moderate | 4 - Moderate | 5 - Moderate to severe | 6 - Severe | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 18.9 | 32.1 | 21.7 | 14.2 | 10.4 | 2.8 | 0 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 13.9 | 25.7 | 19.8 | 23.8 | 12.9 | 4.0 | 0 |
Modified Rosacea Severity Scoring System evaluating four signs of rosacea, flushing (transient erythema or redness), erythema (redness), papules and pustules and telangiectasia (spider-veins) ranges from 0 (best, absent) to 12 (worst, severe on all items) (NCT00395226)
Timeframe: 90 days
| Intervention | units on scale 0 to 12 (Mean) |
|---|---|
| Placebo (Lactose) | 4.9 |
| Zinc Sulfate | 5.1 |
52 reviews available for metronidazole and Rosacea
| Article | Year |
|---|---|
Advances in pharmacotherapy for rosacea: what is the current state of the art?
Topics: Dermatologic Agents; Erythema; Guidelines as Topic; Humans; Metronidazole; Quality of Life; Rosacea | 2022 |
Neurogenic Rosacea Treatment: A Literature Review.
Topics: Anti-Bacterial Agents; Brimonidine Tartrate; Erythema; Humans; Metronidazole; Rosacea | 2023 |
Treatment of pediatric ocular rosacea: A systematic review.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Doxycycline; Female; Humans; Male; Metronidazole; Ro | 2023 |
Treatment of Demodex-associated inflammatory skin conditions: A systematic review.
Topics: Administration, Topical; Benzoates; Folliculitis; Humans; Metronidazole; Mite Infestations; Permethr | 2019 |
Symptomatic vulvar demodicosis: A case report and review of the literature.
Topics: Administration, Oral; Administration, Topical; Adult; Animals; Antiparasitic Agents; Antiprotozoal A | 2020 |
Treatment of rosacea during pregnancy.
Topics: Adult; Algorithms; Animals; Anti-Bacterial Agents; Azithromycin; Brimonidine Tartrate; Dermatologic | 2021 |
A Review of the Current Modalities for the Treatment of Papulopustular Rosacea.
Topics: Administration, Cutaneous; Anti-Infective Agents; Dermatologic Agents; Dicarboxylic Acids; Doxycycli | 2018 |
Rosacea First-choice treatments.
Topics: Administration, Cutaneous; Administration, Oral; Adrenergic alpha-2 Receptor Agonists; Anti-Bacteria | 2017 |
Spanish Consensus Document on the Treatment Algorithm for Rosacea.
Topics: Algorithms; Anti-Bacterial Agents; Brimonidine Tartrate; Consensus; Delphi Technique; Doxycycline; H | 2019 |
An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea.
Topics: Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Humans; Immunity, Innate; Inflammation; Low-Le | 2013 |
Interventions for rosacea.
Topics: Anti-Infective Agents; Brimonidine Tartrate; Cyclosporine; Dermatologic Agents; Dicarboxylic Acids; | 2015 |
Granulomatous Rosacea and Periorificial Dermatitis: Controversies and Review of Management and Treatment.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Benzoyl Peroxide; Dermatitis, Perioral; Dermatologic | 2015 |
Ivermectin: A Review in Rosacea.
Topics: Administration, Cutaneous; Anti-Infective Agents; Antiparasitic Agents; Drug Administration Schedule | 2015 |
Drugs for rosacea.
Topics: Administration, Oral; Administration, Topical; Animals; Anti-Bacterial Agents; Dermatologic Agents; | 2016 |
Canadian Clinical Practice Guidelines for Rosacea.
Topics: Anti-Infective Agents; Consensus; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Eye Diseases | 2016 |
Topical and oral therapeutic approach to rosacea.
Topics: Administration, Cutaneous; Administration, Oral; Brimonidine Tartrate; Dermatologic Agents; Dicarbox | 2016 |
The cost-effectiveness of rosacea treatments.
Topics: Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Anti-Inflammatory Agents; Clin | 2009 |
Current topical and systemic approaches to treatment of rosacea.
Topics: Administration, Oral; Administration, Topical; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; | 2009 |
Updates on the pathophysiology and management of acne rosacea.
Topics: Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Dermatologic Agents; Dicarboxy | 2009 |
A review of the diagnosis and treatment of rosacea.
Topics: Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Anti-Infective Agents; Dermato | 2010 |
Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: a case series and a literature review of therapeutic approaches.
Topics: Aged; Antineoplastic Agents; Dermatologic Agents; Drug Eruptions; ErbB Receptors; Female; Humans; Ma | 2010 |
Innovative use of topical metronidazole.
Topics: Acute Generalized Exanthematous Pustulosis; Administration, Cutaneous; Adult; Anti-Infective Agents; | 2010 |
[Rosacea: pathogenesis, clinical forms and therapy].
Topics: Administration, Cutaneous; Administration, Oral; Anti-Infective Agents; Anti-Infective Agents, Local | 2010 |
Clinical inquiries. What is the most effective treatment for acne rosacea?
Topics: Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Anti-Infective Agents; Dermato | 2011 |
Interventions for rosacea.
Topics: Anti-Infective Agents; Cyclosporine; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Humans; M | 2011 |
Optimal management of papulopustular rosacea: rationale for combination therapy.
Topics: Administration, Cutaneous; Administration, Oral; Anti-Inflammatory Agents; Dermatologic Agents; Dica | 2012 |
A status report on the medical management of rosacea: focus on topical therapies.
Topics: Administration, Topical; Anti-Infective Agents; Anti-Infective Agents, Local; Dermatologic Agents; D | 2002 |
Identifying rosacea: what all dentists should know.
Topics: Administration, Topical; Adult; Anti-Infective Agents, Local; Dentists; Diagnosis, Differential; Hum | 2003 |
Medical treatment of rosacea with emphasis on topical therapies.
Topics: Administration, Topical; Anti-Infective Agents, Local; Clinical Trials as Topic; Dermatologic Agents | 2004 |
The role of topical metronidazole in the treatment of rosacea.
Topics: Administration, Topical; Anti-Infective Agents; Dicarboxylic Acids; Humans; Metronidazole; Rosacea | 2004 |
Reactive oxygen species and rosacea.
Topics: Anti-Infective Agents; Antioxidants; Humans; Metronidazole; Neutrophils; Reactive Oxygen Species; Ro | 2004 |
Rosacea. An overview of diagnosis and management.
Topics: Anti-Infective Agents; Body Image; Dermatologic Agents; Diagnosis, Differential; Dicarboxylic Acids; | 2004 |
Present and future rosacea therapy.
Topics: Anti-Infective Agents; Biomedical Research; Chronic Disease; Dermatologic Agents; Dicarboxylic Acids | 2005 |
The rigor of trials evaluating Rosacea treatments.
Topics: Anti-Infective Agents; Dermatologic Agents; Dicarboxylic Acids; Gels; Humans; Metronidazole; Randomi | 2005 |
Face up to rosacea.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Dermatologic Agents; Diagnosis, Differential; Dicar | 2005 |
Topical therapies for rosacea.
Topics: Administration, Topical; Dicarboxylic Acids; Humans; Metronidazole; Rosacea; Sulfacetamide | 2006 |
A clinical overview of azelaic acid.
Topics: Administration, Cutaneous; Chemistry, Pharmaceutical; Dermatologic Agents; Dicarboxylic Acids; Human | 2006 |
An update on the role of topical metronidazole in rosacea.
Topics: Administration, Cutaneous; Anti-Infective Agents; Drug Therapy, Combination; Humans; Metronidazole; | 2006 |
Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter?
Topics: Administration, Cutaneous; Chronic Disease; Clinical Trials, Phase III as Topic; Dosage Forms; Dose- | 2006 |
[Rosacea and UV light].
Topics: Humans; Metronidazole; Radiation-Sensitizing Agents; Rosacea; Sunscreening Agents; Ultraviolet Rays | 2006 |
Systematic review of rosacea treatments.
Topics: Administration, Cutaneous; Administration, Oral; Anti-Bacterial Agents; Benzoyl Peroxide; Cosmetics; | 2007 |
Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics.
Topics: Anti-Bacterial Agents; Clinical Trials as Topic; Dermatologic Agents; Dicarboxylic Acids; Doxycyclin | 2007 |
Perioral dermatitis.
Topics: Adrenal Cortex Hormones; Adult; Aged; Child; Dermatitis; Diagnosis, Differential; Facial Dermatoses; | 1995 |
May Helicobacter pylori be important for dermatologists?
Topics: Bacterial Toxins; Case-Control Studies; Chronic Disease; Gastric Mucosa; Helicobacter Infections; He | 1995 |
Rosacea-like demodicosis in an HIV-positive child.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitrichomonal Agents; Child, Prescho | 1996 |
Rosacea: how to recognize and treat an age-related skin disease.
Topics: Anti-Bacterial Agents; Diagnosis, Differential; Disease Progression; Humans; Laser Therapy; Metronid | 1997 |
Use of topical products for maintaining remission in rosacea.
Topics: Administration, Topical; Anti-Infective Agents; Humans; Metronidazole; Rosacea; Skin; Tetracycline | 1999 |
Acne and rosacea. New and emerging therapies.
Topics: Acne Vulgaris; Aged; Anti-Bacterial Agents; Helicobacter Infections; Helicobacter pylori; Humans; Is | 2000 |
Identifying and treating rosacea.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Diagnosis, Differential; Disease Progression; Drug The | 2001 |
Topical metronidazole for rosacea.
Topics: Administration, Topical; Clinical Trials as Topic; Humans; Metronidazole; Rosacea | 2002 |
Demodicidosis revisited.
Topics: Adult; Age Distribution; Animals; Biopsy, Needle; Child; Child, Preschool; Diagnosis, Differential; | 2002 |
Topical metronidazole: a new therapy for rosacea.
Topics: Administration, Topical; Animals; Humans; Metronidazole; Rosacea | 1990 |
60 trials available for metronidazole and Rosacea
| Article | Year |
|---|---|
Metronidazole gel (0.75%) in Japanese patients with rosacea: A randomized, vehicle-controlled, phase 3 study.
Topics: Dermatologic Agents; Double-Blind Method; Humans; Japan; Metronidazole; Rosacea; Treatment Outcome | 2022 |
Perspectives on rosacea patient characteristics and quality of life using baseline data from a phase 3 clinical study conducted in Japan.
Topics: Adult; Female; Humans; Japan; Male; Metronidazole; Middle Aged; Quality of Life; Rosacea | 2022 |
Topical Metronidazole Versus Ivermectin for Low-density Demodex Rosacea: A Rater-blinded, Randomized, Split-face Trial.
Topics: Animals; Humans; Ivermectin; Metronidazole; Mites; Rosacea | 2022 |
Color Doppler ultrasonographic evaluation of management of papulopustular rosacea.
Topics: Administration, Cutaneous; Adult; Drug Therapy, Combination; Female; Follow-Up Studies; Healthy Volu | 2021 |
Natural Skin Care Products as Adjunctive to Prescription Therapy in Moderate to Severe Rosacea
Topics: Adult; Aged; Biological Products; Combined Modality Therapy; Dermatologic Agents; Female; Humans; Ma | 2019 |
Evaluation of the efficacy and tolerance of artemether emulsion for the treatment of papulopustular rosacea: a randomized pilot study.
Topics: Adult; Artemether; Drug Administration Schedule; Emulsions; Female; Humans; Male; Metronidazole; Mid | 2019 |
Management of rosacea-prone skin: evaluation of a skincare product containing Ambophenol, Neurosensine, and La Roche-Posay Thermal spring water as monotherapy or adjunctive therapy.
Topics: Adolescent; Adult; Dermatologic Agents; Double-Blind Method; Drug Packaging; Female; Follow-Up Studi | 2013 |
[Angioprotectors in the treatment of rosacea].
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Ascorbic Acid; Derma | 2014 |
Superiority of ivermectin 1% cream over metronidazole 0·75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Dermatologic Agents; Female; | 2015 |
Dapsone Gel in the Treatment of Papulopustular Rosacea: A Double-Blind Randomized Clinical Trial.
Topics: Administration, Topical; Adult; Anti-Infective Agents; Dapsone; Double-Blind Method; Female; Gels; H | 2015 |
Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study.
Topics: Humans; Ivermectin; Metronidazole; Remission Induction; Rosacea | 2016 |
Ivermectin cream improves health-related quality of life in patients with rosacea: data from a randomized trial.
Topics: Adolescent; Adult; Aged; Dermatologic Agents; Humans; Ivermectin; Metronidazole; Middle Aged; Ointme | 2016 |
Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea.
Topics: Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Anti-Infective Agents, Local; | 2008 |
Comparative study of some treatment modalities of rosacea.
Topics: Adult; Dicarboxylic Acids; Double-Blind Method; Female; Humans; Male; Metronidazole; Middle Aged; Pe | 2009 |
A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial.
Topics: Administration, Topical; Adult; Analysis of Variance; Anti-Infective Agents; Dermatologic Agents; Em | 2010 |
Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: a case series and a literature review of therapeutic approaches.
Topics: Aged; Antineoplastic Agents; Dermatologic Agents; Drug Eruptions; ErbB Receptors; Female; Humans; Ma | 2010 |
Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea.
Topics: Administration, Oral; Administration, Topical; Adult; Aged; Dicarboxylic Acids; Doxycycline; Drug Th | 2010 |
Efficacy of 1% terbinafine cream in comparison with 0.75% metronidazole gel for the treatment of papulopustular rosacea.
Topics: Adult; Aged; Anti-Infective Agents; Female; Humans; Male; Metronidazole; Middle Aged; Naphthalenes; | 2011 |
Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial.
Topics: Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Anti-Infective Agents; Delayed | 2010 |
The appearance of facial foundation cosmetics applied after metronidazole gel 1%.
Topics: Administration, Cutaneous; Adult; Aged; Cosmetics; Dermatologic Agents; Erythema; Female; Gels; Huma | 2011 |
Efficacy of a novel rosacea treatment system: an investigator-blind, randomized, parallel-group study.
Topics: Administration, Cutaneous; Dermatologic Agents; Erythema; Female; Gels; Humans; Metronidazole; Middl | 2011 |
Preparation and evaluation of topical microemulsion system containing metronidazole for remission in rosacea.
Topics: Administration, Topical; Adult; Double-Blind Method; Emulsions; Erythema; Female; Humans; Male; Metr | 2012 |
[New possibilities in the treatment of early stages of rosacea].
Topics: Administration, Topical; Adrenergic beta-Antagonists; Adult; Anti-Bacterial Agents; Erythema; Female | 2013 |
Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Enzyme Inhibitors; | 2002 |
A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Dermatologic Agents; Dicarboxylic Acids; Do | 2003 |
Efficiency of benzoyl peroxide-erythromycin gel in comparison with metronidazole gel in the treatment of acne rosacea.
Topics: Administration, Cutaneous; Anti-Infective Agents; Benzoyl Peroxide; Drug Therapy, Combination; Eryth | 2004 |
Adapalene vs. metronidazole gel for the treatment of rosacea.
Topics: Adapalene; Adult; Aged; Dermatologic Agents; Female; Gels; Humans; Male; Metronidazole; Middle Aged; | 2005 |
Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea.
Topics: Analysis of Variance; Drug Therapy, Combination; Female; Humans; Least-Squares Analysis; Male; Metro | 2005 |
A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea.
Topics: Administration, Topical; Adult; Anti-Infective Agents; Double-Blind Method; Doxycycline; Drug Therap | 2005 |
Gel vehicles are not inherently more irritating than creams.
Topics: Administration, Cutaneous; Adult; Chemistry, Pharmaceutical; Dermatitis, Contact; Dermatologic Agent | 2006 |
Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea.
Topics: Administration, Cutaneous; Adult; Aged; Dermatologic Agents; Dicarboxylic Acids; Drug Administration | 2006 |
A look at the safety of metronidazole 1% gel: cumulative irritation, contact sensitization, phototoxicity, and photoallergy potential.
Topics: Dermatitis, Contact; Dermatitis, Photoallergic; Dermatitis, Phototoxic; Dermatologic Agents; Erythem | 2006 |
A novel aqueous metronidazole 1% gel with hydrosolubilizing agents (HSA-3).
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Chemistry, Pharmaceutical; Dermatologic Agents; | 2006 |
Skin tolerance, efficacy, and quality of life of patients with red facial skin using a skin care regimen containing Licochalcone A.
Topics: Adult; Aged; Chalcones; Drug Therapy, Combination; Erythema; Face; Female; Humans; Male; Metronidazo | 2006 |
The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea.
Topics: Administration, Cutaneous; Adult; Anti-Infective Agents; Erythema; Female; Follow-Up Studies; Gels; | 2007 |
Cumulative irritation potential among metronidazole gel 1%, metronidazole gel 0.75%, and azelaic acid gel 15%.
Topics: Administration, Topical; Adult; Dermatologic Agents; Dicarboxylic Acids; Drug Eruptions; Female; Gel | 2007 |
Beneficial use of Cetaphil moisturizing cream as part of a daily skin care regimen for individuals with rosacea.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Anti-Infective Agents; Drug Administration Sched | 2007 |
Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Capsules; Delayed-Action Preparations; Di | 2007 |
Treatment of rosacea with i% metronidazole cream. A double-blind study.
Topics: Administration, Topical; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Erythema; Femal | 1983 |
[Acne rosacea. Efficacy of a metronidazole cream].
Topics: Double-Blind Method; Humans; Metronidazole; Ointments; Rosacea | 1983 |
A double-blind study of I% metronidazole cream versus systemic oxytetracycline therapy for rosacea.
Topics: Administration, Oral; Administration, Topical; Adult; Clinical Trials as Topic; Double-Blind Method; | 1983 |
A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea.
Topics: Clinical Trials as Topic; Double-Blind Method; Humans; Metronidazole; Oxytetracycline; Rosacea | 1980 |
[Double-blind study versus excipient of 0.75% metronidazole gel in the treatment of rosacea].
Topics: Administration, Topical; Adult; Double-Blind Method; Excipients; Female; Gels; Humans; Male; Metroni | 1993 |
A pilot study of 5 percent permethrin cream versus 0.75 percent metronidazole gel in acne rosacea.
Topics: Administration, Topical; Adult; Aged; Antitrichomonal Agents; Female; Humans; Male; Metronidazole; M | 1995 |
The efficacy of topical metronidazole in the treatment of ocular rosacea.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Blepharitis; Double-Blind Method; Female; G | 1996 |
A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Double-Blind Meth | 1998 |
Topical metronidazole maintains remissions of rosacea.
Topics: Administration, Cutaneous; Adult; Aged; Anti-Bacterial Agents; Dermatologic Agents; Double-Blind Met | 1998 |
The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial.
Topics: Administration, Topical; Adult; Double-Blind Method; Drug Administration Schedule; Humans; Metronida | 1998 |
A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea.
Topics: Administration, Topical; Adult; Aged; Dermatologic Agents; Dicarboxylic Acids; Double-Blind Method; | 1999 |
Helicobacter pylori and its eradication in rosacea.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Dy | 1999 |
Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea.
Topics: Administration, Topical; Adult; Aged; Anti-Infective Agents; Dose-Response Relationship, Drug; Drug | 2001 |
Treatment of rosacea by metronidazole.
Topics: Administration, Oral; Adult; Aged; Clinical Trials as Topic; Drug Evaluation; Humans; Metronidazole; | 1976 |
Topical metronidazole for severe and recalcitrant rosacea: a prospective open trial.
Topics: Administration, Topical; Adult; Aged; Clinical Trials as Topic; Facial Dermatoses; Female; Humans; M | 1989 |
Topical metronidazole for rosacea.
Topics: Administration, Cutaneous; Animals; Clinical Trials as Topic; Double-Blind Method; Gels; Humans; Met | 1989 |
[Rosacea. Clinical features and treatment].
Topics: Clinical Trials as Topic; Double-Blind Method; Humans; Male; Metronidazole; Middle Aged; Multicenter | 1989 |
Topical metronidazole in the treatment of rosacea.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Double-Blind Meth | 1986 |
Evaluation of topical metronidazole gel in acne rosacea.
Topics: Administration, Topical; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Erythema; Femal | 1987 |
Topical metronidazole therapy for rosacea.
Topics: Adult; Double-Blind Method; Drug Evaluation; Erythema; Female; Humans; Male; Metronidazole; Random A | 1987 |
[Metronidazole cream for the local treatment of rosacea].
Topics: Administration, Topical; Clinical Trials as Topic; Double-Blind Method; Humans; Metronidazole; Rosac | 1988 |
[Rosacea].
Topics: Body Temperature; Clinical Trials as Topic; Clonidine; Female; Humans; Isotretinoin; Male; Metronida | 1988 |
122 other studies available for metronidazole and Rosacea
| Article | Year |
|---|---|
S2k guideline: Rosacea.
Topics: Brimonidine Tartrate; Dermatologic Agents; Erythema; Humans; Ivermectin; Metronidazole; Rosacea | 2022 |
Enhanced skin localization of metronidazole using solid lipid microparticles incorporated into polymeric hydrogels for potential improved of rosacea treatment: An ex vivo proof of concept investigation.
Topics: Antioxidants; Gels; Humans; Hydrogels; Lipids; Metronidazole; Proof of Concept Study; Rosacea | 2022 |
Epsolay - a benzoyl peroxide cream for rosacea.
Topics: Administration, Cutaneous; Benzoyl Peroxide; Dermatologic Agents; Humans; Metronidazole; Rosacea | 2023 |
Epsolay™ (Microencapsulated Benzoyl Peroxide 5%) Cream for the Topical Treatment of Rosacea.
Topics: Administration, Topical; Benzoyl Peroxide; Dermatologic Agents; Emollients; Humans; Metronidazole; R | 2023 |
Therapeutic effects of mesoderm introduction of compound glycyrrhizin injection on the treatment of rosacea.
Topics: Erythema; Glycyrrhizic Acid; Humans; Metronidazole; Quality of Life; Rosacea | 2023 |
Ocular rosacea associated with transient monocular vision loss: resolution with oral metronidazole.
Topics: Humans; Metronidazole; Rosacea; Vision, Monocular | 2023 |
[Granulomatous rosacea in a lung transplant recipient : A possible therapy option in a unique group of patients].
Topics: Aged; Animals; Humans; Immunocompromised Host; Insecticides; Ivermectin; Metronidazole; Mite Infesta | 2020 |
Topical treatments for rosacea.
Topics: Administration, Topical; Dicarboxylic Acids; Drug Costs; Humans; Ivermectin; Metronidazole; Patient | 2019 |
Development of an emulgel for the treatment of rosacea using quality by design approach.
Topics: Chemistry, Pharmaceutical; Cosmetics; Drug Delivery Systems; Drug Liberation; Excipients; Gels; Huma | 2020 |
Use of permethrin in the treatment of rosacea fulminans during pregnancy: One case report.
Topics: Adult; Anti-Bacterial Agents; Female; Humans; Ivermectin; Metronidazole; Permethrin; Pregnancy; Rosa | 2020 |
Rosacea Treatment Satisfaction: Matching Adjusted Indirect Treatment Comparison Analysis of Metronidazole Gel or Cream vs Azelaic Acid Foam.
Topics: Adolescent; Adult; Dermatologic Agents; Female; Humans; Male; Metronidazole; Patient Satisfaction; R | 2020 |
Pediatric Demodicosis Associated with Gain-of-Function Variant in STAT1 Presenting as Rosacea-Type Rash.
Topics: Alleles; Child; DNA Mutational Analysis; Exanthema; Female; Gain of Function Mutation; Genetic Assoc | 2021 |
Rosacea.
Topics: Dermatologic Agents; Doxycycline; Humans; Metronidazole; Phototherapy; Rosacea | 2021 |
Rosacea: An Update in Diagnosis, Classification and Management.
Topics: Brimonidine Tartrate; Dermatologic Agents; Doxycycline; Humans; Metronidazole; Rosacea | 2021 |
Rosacea.
Topics: Anti-Bacterial Agents; Brimonidine Tartrate; Diagnosis, Differential; Doxycycline; Humans; Isotretin | 2017 |
Defining treatment success in rosacea as 'clear' may provide multiple patient benefits: results of a pooled analysis.
Topics: Adult; Aged; Dermatologic Agents; Female; Humans; Ivermectin; Male; Metronidazole; Middle Aged; Qual | 2017 |
Granulomatous rosacea: a case report.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Humans; Male; Metronidazole; Middle Aged; M | 2017 |
A photoconverter gel-assisted blue light therapy for the treatment of rosacea.
Topics: Gels; Humans; Metronidazole; Phototherapy; Rosacea; Treatment Outcome | 2017 |
Clinical characteristics and management of patients with rosacea in a tertiary dermatology center in Singapore from 2009 to 2013.
Topics: Adult; Age Distribution; Aged; Anti-Infective Agents; Cohort Studies; Databases, Factual; Disease Ma | 2018 |
Prescription to Over-the-Counter Switch of Metronidazole and Azelaic Acid for Treatment of Rosacea.
Topics: Anti-Infective Agents; Dermatologic Agents; Diagnostic Self Evaluation; Dicarboxylic Acids; Humans; | 2018 |
Trends in utilization of topical medications for treatment of rosacea in the United States (2005-2014): A cohort analysis.
Topics: Administration, Cutaneous; Adult; Anti-Bacterial Agents; Cohort Studies; Dermatologic Agents; Dicarb | 2019 |
Metronidazole-loaded nanostructured lipid carriers to improve skin deposition and retention in the treatment of rosacea.
Topics: Administration, Topical; Animals; Chemistry, Pharmaceutical; Drug Carriers; Drug Delivery Systems; D | 2019 |
Unusual case of rosacea fulminans after topical metronidazole application.
Topics: Administration, Cutaneous; Adult; Drug Therapy, Combination; Facial Dermatoses; Female; Humans; Isot | 2019 |
[Topical therapy of rosacea].
Topics: Administration, Topical; Anti-Inflammatory Agents; Dermatologic Agents; Dicarboxylic Acids; Humans; | 2013 |
Patterns of ambulatory care usage and leading treatments for rosacea.
Topics: Administration, Oral; Administration, Topical; Ambulatory Care; Anti-Infective Agents; Dermatology; | 2014 |
Acne vulgaris in the context of complex medical co-morbities: the management of severe acne vulgaris in a female with retinitis pigmentosa - utilizing pulse dye laser in conjunction with medical therapy.
Topics: Acne Vulgaris; Administration, Cutaneous; Adult; Androstenes; Anti-Infective Agents, Local; Combined | 2014 |
In vitro/in vivo characterization of nanoemulsion formulation of metronidazole with improved skin targeting and anti-rosacea properties.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Chromatography, High Pressure Liquid; Croto | 2014 |
Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea.
Topics: Administration, Cutaneous; Administration, Oral; Adrenergic alpha-2 Receptor Agonists; Anti-Infectiv | 2014 |
Treatment of symptoms of erythemato-telangiectatic rosacea with topical potassium azeloyl diglycinate and hydroxypropyl chitosan: Results of a sponsor-free, multicenter, open study.
Topics: Administration, Cutaneous; Adult; Aged; Chitosan; Dermatologic Agents; Female; Glycine; Humans; Male | 2015 |
Update on the management of rosacea: a status report on the current role and new horizons with topical azelaic acid.
Topics: Administration, Cutaneous; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Drug Therapy, Combi | 2014 |
Reflectance confocal microscopy for monitoring the density of Demodex mites in patients with rosacea before and after treatment.
Topics: Adult; Aged; Animals; Anti-Infective Agents; Doxycycline; Drug Therapy, Combination; Facial Dermatos | 2015 |
Rosacea: Diagnosis and Treatment.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Dermatologic Agents; Education, Medical, Cont | 2015 |
Ivermectin cream for rosacea.
Topics: Adult; Clinical Trials as Topic; Dicarboxylic Acids; Drug Interactions; Humans; Ivermectin; Metronid | 2015 |
Rosacea and abatacept: the first report of a possible correlation.
Topics: Abatacept; Anti-Bacterial Agents; Anti-Infective Agents; Antirheumatic Agents; Arthritis, Rheumatoid | 2016 |
Cost-Effectiveness of Ivermectin 1% Cream in Adults with Papulopustular Rosacea in the United States.
Topics: Adult; Cost-Benefit Analysis; Drug Compounding; Female; Humans; Ivermectin; Male; Metronidazole; Ros | 2016 |
A Sequential Approach to the Treatment of Severe Papulopustular Rosacea Not Responding to Traditional Treatment.
Topics: Administration, Cutaneous; Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Derma | 2016 |
A Tailored Approach to the Treatment of a Patient with a Severe Dynamic Manifestation of Rosacea: A Case Report.
Topics: Administration, Topical; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Brimonidine Tartrat | 2016 |
Concomitant allergic contact dermatitis from diphenhydramine and metronidazole.
Topics: Anti-Infective Agents; Dermatitis, Allergic Contact; Diphenhydramine; Drug Eruptions; Drug Therapy, | 2008 |
Rosacea-like demodicidosis.
Topics: Diagnostic Errors; Female; Humans; Metronidazole; Middle Aged; Mite Infestations; Rosacea | 2008 |
Prescription refills and healthcare costs associated with topical metronidazole in Medicaid enrolled patients with rosacea.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Infective Agents; Child; Child, Preschool; Dr | 2008 |
Contact sensitization to metronidazole from possible occupational exposure.
Topics: Administration, Topical; Adult; Aged; Carcinoma, Basal Cell; Dermatitis, Allergic Contact; Dermatiti | 2009 |
Rosacea and its topical management.
Topics: Administration, Cutaneous; Dermatologic Agents; Dicarboxylic Acids; Humans; Metronidazole; Rosacea; | 2009 |
Anti-inflamatory dose doxycycline in the treatment of rosacea.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Clinical Trials as Topic; Dose-Response Relationshi | 2009 |
Red nose: primary cutaneous marginal zone B-cell lymphoma.
Topics: Administration, Topical; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Antineopla | 2010 |
[Sunscreen, antibiotics, laser. What can you do against rosacea?].
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Child; Contraindications; Dermatologic Agents; Doxyc | 2009 |
Evaluation of mechanical and rheological properties of metronidazole gel as local delivery system.
Topics: Adhesiveness; Administration, Cutaneous; Animals; Anti-Infective Agents; Excipients; Gels; Hardness; | 2011 |
[Metronidazole: alternative treatment for ocular and cutaneous rosacea in the pediatric population].
Topics: Adolescent; Anti-Infective Agents; Child; Child, Preschool; Disease Progression; Eye Diseases; Femal | 2011 |
[Treatment of rosacea].
Topics: Adapalene; Anti-Infective Agents; Cyclosporine; Dermatologic Agents; Dicarboxylic Acids; Humans; Imm | 2011 |
Treatment of rosacea.
Topics: Anti-Infective Agents; Cyclosporine; Dermatologic Agents; Dicarboxylic Acids; Humans; Immunosuppress | 2011 |
Rosacea with severe ophthalmic involvement and blindness - a rare occurrence.
Topics: Administration, Ophthalmic; Adult; Anti-Bacterial Agents; Blindness; Clindamycin; Doxycycline; Eye D | 2012 |
[Acantholytic rosacea of the forehead and scalp in a patient with Hailey-Hailey disease].
Topics: Acantholysis; Administration, Oral; Administration, Topical; Alopecia; Anti-Bacterial Agents; Anti-I | 2012 |
Rosacea: update on management and emerging therapies.
Topics: Administration, Cutaneous; Adrenergic Agents; Anti-Infective Agents; Antiparasitic Agents; Brimonidi | 2012 |
Rosacea: More than just red in the face.
Topics: Adult; Age Factors; Anti-Bacterial Agents; Anti-Infective Agents; Female; Humans; Metronidazole; Mid | 2002 |
Is permethrin 5% cream effective for rosacea?
Topics: Animals; Antitrichomonal Agents; Evidence-Based Medicine; Humans; Insecticides; Metronidazole; Mite | 2003 |
Co-existing sensitivity to metronidazole and isothiazolinone.
Topics: Aged; Anti-Infective Agents; Dermatitis, Contact; Drug Combinations; Drug Eruptions; Drug Interactio | 2003 |
The treatment of rosacea.
Topics: Anti-Infective Agents; Anti-Infective Agents, Local; Humans; Low-Level Light Therapy; Metronidazole; | 2004 |
Comparison of 15% azelaic acid gel and 0.75% metronidazole gel for the topical treatment of papulopustular rosacea.
Topics: Administration, Cutaneous; Clinical Trials as Topic; Dermatologic Agents; Dicarboxylic Acids; Gels; | 2004 |
Diagnosing and managing the patient with rosacea.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Drug Administration Routes; Faci | 2005 |
Rosacea fulminans in pregnancy: case report and review of the literature.
Topics: Administration, Oral; Administration, Topical; Adult; Anti-Infective Agents; Anti-Inflammatory Agent | 2006 |
[What is recommended in rosacea?].
Topics: Administration, Oral; Administration, Topical; Humans; Male; Metronidazole; Middle Aged; Minocycline | 2006 |
Rosacea trial comparing twice-daily azelaic acid gel 15% with once-daily metronidazole gel 1%.
Topics: Anti-Infective Agents; Dermatologic Agents; Dicarboxylic Acids; Drug Administration Schedule; Humans | 2007 |
Azelaic acid gel 15%: clinical versatility in the treatment of rosacea.
Topics: Dermatologic Agents; Dicarboxylic Acids; Dose-Response Relationship, Drug; Drug Administration Sched | 2006 |
Allergic contact dermatitis to topical metronidazole - 3 cases.
Topics: Administration, Topical; Adult; Anti-Infective Agents; Dermatitis, Allergic Contact; Drug Eruptions; | 2007 |
The effect of methylcellulose on metronidazole release from polyacrylic acid hydrogels.
Topics: Acrylic Resins; Anti-Infective Agents; Chemistry, Pharmaceutical; Hydrogels; Hydrogen-Ion Concentrat | 2007 |
Scavenging properties of metronidazole on free oxygen radicals in a skin lipid model system.
Topics: Antioxidants; Cell-Free System; Dose-Response Relationship, Drug; Free Radicals; Lipid Peroxidation; | 2007 |
In reference to the October 2004 comprehensive overview of rosacea therapy.
Topics: Clinical Trials as Topic; Dermatologic Agents; Dicarboxylic Acids; Humans; Metronidazole; Rosacea | 2007 |
Cutaneous and ocular signs of childhood rosacea.
Topics: Adolescent; Blepharitis; Chalazion; Child; Child, Preschool; Conjunctivitis; Corneal Ulcer; Eye Dise | 2008 |
Asymptomatic eruption of the face of a 68-year-old woman.
Topics: Aged; Anti-Infective Agents; Diagnosis, Differential; Doxycycline; Female; Humans; Metronidazole; Ro | 2008 |
Metronidazole and Demodex folliculorum.
Topics: Hair; Humans; Metronidazole; Mites; Rosacea | 1981 |
[Metronidazole therapy in rosacea].
Topics: Humans; Metronidazole; Rosacea | 1982 |
[Metronidazole in the treatment of rosacea and perioral dermatitis].
Topics: Adult; Aged; Facial Dermatoses; Female; Humans; Male; Metronidazole; Middle Aged; Mouth; Rosacea | 1983 |
[Problems in the treatment of acne rosacea].
Topics: Adult; Aged; Aspirin; Chloroquine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; M | 1982 |
[Local treatment of rosacea with imidazole derivatives].
Topics: Administration, Topical; Adult; Aged; Clotrimazole; Econazole; Female; Humans; Imidazoles; Male; Met | 1983 |
The relapse rate for rosacea after treatment with either oral tetracycline or metronidazole cream.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Male; Metronidazole; Middle Aged; Recurrence; Rosace | 1983 |
[Metronidazole therapy of rosacea. The drug and its indications].
Topics: Biotransformation; Female; Humans; Metabolic Clearance Rate; Metronidazole; Pregnancy; Rosacea | 1983 |
[Papulopustular rosacea (traditional acne rosacea)].
Topics: Adult; Diagnosis, Differential; Female; Humans; Male; Metronidazole; Middle Aged; Riboflavin; Rosace | 1983 |
[Use of trichopol to treat acne rosacea].
Topics: Adult; Female; Humans; Male; Metronidazole; Middle Aged; Rosacea | 1984 |
[Rosacea and demodicosis (a review of the literature)].
Topics: Animals; Cryosurgery; Dermabrasion; Electrocoagulation; Humans; Metronidazole; Mite Infestations; Mi | 1984 |
[Treatment of rosacea with metronidazole internally and externally].
Topics: Administration, Oral; Administration, Topical; Adult; Drug Administration Schedule; Female; Humans; | 1984 |
Metronidazole in the treatment of rosacea.
Topics: Humans; Metronidazole; Rosacea | 1984 |
Metronidazole suspension applied topically for rosacea.
Topics: Female; Humans; Male; Metronidazole; Rosacea; Suspensions | 1984 |
[Pathogenesis and treatment of rosacea and perioral dermatitis].
Topics: Adolescent; Adult; Aged; Calcium Gluconate; Drug Therapy, Combination; Facial Dermatoses; Female; Ga | 1980 |
[Metronidazol--its therapeutical uses in rosacea (author's transl)].
Topics: Female; Humans; Male; Metronidazole; Rosacea | 1980 |
Rosacea, metronidazole and pregnancy.
Topics: Carcinogens; Female; Humans; Metronidazole; Pregnancy; Pregnancy Complications; Rosacea; Teratogens; | 1980 |
[Trichopol treatment of rosacea].
Topics: Adult; Chronic Disease; Drug Evaluation; Female; Humans; Male; Metronidazole; Middle Aged; Rosacea; | 1981 |
Demodicidosis or rosacea: what did we treat?
Topics: Aged; Animals; Diagnosis, Differential; Facial Dermatoses; Humans; Male; Metronidazole; Mite Infesta | 1995 |
Helicobacter pylori in patients with rosacea.
Topics: Antibodies, Bacterial; Duodenitis; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; | 1994 |
[Metronidazole, alcohol and rosacea].
Topics: Administration, Topical; Alcohol Drinking; Disulfiram; Drug Synergism; Ethanol; Humans; Metronidazol | 1993 |
Acne rosacea and Helicobacter pylori betrothed.
Topics: Administration, Oral; Animals; Antitrichomonal Agents; Helicobacter Infections; Helicobacter pylori; | 1996 |
Rosacea.
Topics: Aged; Anti-Bacterial Agents; Diagnosis, Differential; Humans; Male; Metronidazole; Rosacea; Tetracyc | 1996 |
[Topical administration of metronidazole gel as an effective therapy alternative in chronic Demodex blepharitis--a case report].
Topics: Administration, Topical; Adult; Animals; Anti-Infective Agents; Blepharitis; Female; Follow-Up Studi | 1998 |
Helicobacter pylori eradication treatment reduces the severity of rosacea.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Antibodies, Bacterial; Bismuth; Female; H | 1999 |
Needs survey of Canadian rosacea patients.
Topics: Administration, Cutaneous; Adult; Anti-Infective Agents; Attitude to Health; Canada; Chi-Square Dist | 1999 |
[Tubero-pustular demodicosis].
Topics: Adult; Anti-Infective Agents; Dermatitis, Atopic; Drug Combinations; Facial Dermatoses; Female; Hexa | 1999 |
Helicobacter pylori: related to rosacea?
Topics: Amoxicillin; Anti-Bacterial Agents; Case-Control Studies; Drug Therapy, Combination; Helicobacter In | 2000 |
Does Helicobacter pylori have a role in the pathogenesis of rosacea?
Topics: Anti-Bacterial Agents; Case-Control Studies; Confounding Factors, Epidemiologic; Helicobacter Infect | 2000 |
Helicobacter pylori and rosacea.
Topics: Administration, Topical; Anti-Bacterial Agents; Bacterial Toxins; Helicobacter Infections; Helicobac | 2000 |
Acne rosacea occurring after carbon dioxide laser treatment.
Topics: Administration, Oral; Administration, Topical; Aged; Anti-Infective Agents; Carbon Dioxide; Female; | 2001 |
A new formulation containing sunscreen (SPF 15) and 1% metronidazole (ROSASOL Cream) in the treatment of rosacea.
Topics: Drug Combinations; Humans; Metronidazole; Rosacea; Sunscreening Agents | 2001 |
Women commonly seek care for rosacea: dermatologists frequently provide the care.
Topics: Administration, Oral; Administration, Topical; Adult; Age Distribution; Aged; Dermatology; Drug Ther | 2001 |
Treatment of rosacea.
Topics: Administration, Oral; Administration, Topical; Benzoyl Peroxide; Humans; Metronidazole; Rosacea; Tet | 2001 |
Resolution of granulomatous rosacea after eradication of Helicobacter pylori with clarithromycin, metronidazole and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 2001 |
Rosacea now successfully controlled with therapy and lifestyle changes.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Drug Therapy, Combination; Humans; Low-Level Light The | 2000 |
[Metronidazole in rosacea].
Topics: Adult; Female; Humans; Male; Metronidazole; Middle Aged; Rosacea | 1978 |
[Treatment of rosacea with metronidazole].
Topics: Humans; Metronidazole; Rosacea | 1978 |
[Acne rosacea].
Topics: Adrenal Cortex Hormones; Adult; Diagnosis, Differential; Female; Humans; Male; Metronidazole; Rosace | 1978 |
[Metronidazole (Flagyl) as a therapy variant in "rosacea" and in "perioral dermatitis" (preliminary report)].
Topics: Drug Evaluation; Facial Dermatoses; Humans; Metronidazole; Rosacea | 1979 |
[Metronidazole therapy in rosacea (author's transl)].
Topics: Adult; Aged; Dermatitis; Female; Gastrointestinal Diseases; Humans; Male; Metronidazole; Middle Aged | 1979 |
Management of rosacea.
Topics: Humans; Metronidazole; Patient Education as Topic; Risk Factors; Rosacea | 1992 |
[Rosacea--a chronic disease of the skin which, if not treated, can cause permanent damage].
Topics: Humans; Metronidazole; Rosacea | 1992 |
Development of an orphan drug by a start-up company. MetroGel for rosacea.
Topics: Administration, Topical; Animals; Drug Industry; Humans; Metronidazole; Orphan Drug Production; Rosa | 1992 |
Idiopathic recalcitrant facial flushing syndrome.
Topics: Facial Dermatoses; Female; Flushing; Humans; Male; Metronidazole; Middle Aged; Rosacea; Syndrome; Te | 1990 |
The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne.
Topics: Acne Vulgaris; Drug Synergism; Fatty Acids, Monounsaturated; Free Radicals; Humans; Inflammation; Me | 1990 |
New topical therapy for acne rosacea offers conspicuous improvement, no systemic effects.
Topics: Administration, Cutaneous; Adult; Double-Blind Method; Female; Humans; Male; Metronidazole; Random A | 1989 |
[A question for the practitioner and the answer. Treatment of rosacea with metronidazole].
Topics: Eyelid Diseases; Humans; Metronidazole; Rosacea | 1989 |
Unilateral demodectic rosacea.
Topics: Adult; Dermatitis; Humans; Male; Metronidazole; Mite Infestations; Rosacea; Toluidines | 1989 |
[External therapy with metronidazole in rosacea].
Topics: Adult; Aged; Female; Humans; Male; Metronidazole; Middle Aged; Rosacea; Tick Infestations | 1985 |
Anti-oxidant action of metronidazole: a possible mechanism of action in rosacea.
Topics: Cells, Cultured; Humans; Metronidazole; Neutrophils; Oxygen; Rosacea | 1986 |
[Therapy of rosacea with bifonazole cream--practical experiences over a 2-year period].
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Imidazoles | 1986 |
Metronidazole in the treatment of rosacea.
Topics: Humans; Metronidazole; Rosacea | 1985 |
[Experience in the treatment of rosacea and perioral dermatitis with trichopol].
Topics: Adolescent; Adult; Aged; Dermatitis; Female; Humans; Male; Metronidazole; Middle Aged; Mouth; Rosace | 1985 |
Treatment of rosacea with tetracycline and metronidazole--a comparative study.
Topics: Adult; Female; Humans; Male; Metronidazole; Prospective Studies; Rosacea; Tetracycline; Time Factors | 1985 |